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 “STUDIES ON SOME HETEROCYCLIC ENTITIES  
OF THERAPEUTIC INTEREST” 
 
A comprehensive summary of the work incorporated in the thesis with the title 
“STUDIES ON SOME HETEROCYCLIC ENTITIES OF THERAPEUTIC 
INTEREST” has been described as under. 
 
PART-I  STUDIES ON 1H-PYRAZOLO[3,4-b]PYRIDINES  
 
Interest in the synthesis of condensed pyrazoles has recently revived because of 
the wide variety of their biological properties. The Pyrazolo-pyridines, which comprise 
five isomers [3,4-b], [3,4-c], [4,3-c], [4,3-b] and [1,5-a], were shown to display high 
biological activity; pyrazolo[4,3-c]pyridine derivatives have use as angiotensin II 
antagonists  which directly stimulates soluble guanylate cyclase  and sensitizes it to its 
physiological stimulator, nitric oxide. 
 
N
N
N
H
 
 
 The usual synthetic routes towards the pyrazolo[4,3-c]pyridine core are ring 
closure of the pyridine ring of a functionised pyrazole or ring closure of the pyrazole ring 
of a functionalised pyridine. The constitution of 1H-Pyrazolo[3,4-b]pyridine was 
represented by Kuczynski. 
 
N
N
N
H
NH2
Type (I)
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1H-pyrazolo[3,4-b]pyridine-3-amine (Type I) have been synthesized  from 
reaction of 2-chloro-3-cyno pyridine with hydrazine hydrate. 
 
 PART- I STUDIES ON SCHIFF BI ASES 
 
Azomethine derivatives have been found to be potent drug in pharmaceutical 
industries and possess a wide spectrum of biological activity. Azomethines are also 
known as Schiff’s base and they are well known interemediate for the preparation of 
azetidinone, thiazolidinone, formazone, arylacetamide and many other derivatives. These 
are the compounds contain characteristic -C=N group. 
Azomethines are obtained mainly by warming the aldehyde and aromatic amine 
together. However, it is more convenient to work in a solvent such as alcohol, dilute 
acetic acid or glacial acetic acid. Some time the reaction is completed by trace of acid in 
other cases the hydrochloride of the amines can be used in the synthesis. 
Looking to the interesting properties of azomethines, we have synthesized some 
new azomethines, which have been described as under. 
 
• Section I: Synthesis and biological evaluation of N-((Z)benzylidine)-1H-
pyrazolo[3,4-b]pyridine-3-amine 
Schiff’s bases possess a wide range of therapeutic activities and intermediate for 
many heterocyclic compounds, hence it appeared of interest to synthesize some new 
Schiff bases of type (II) in association with 1H-pyrazolo[3,4-b]pyridine nucleus.  
 
 
 
N
N
N
H
N CH
R
Type (II)   
R = H, OH, Cl,  OCH3, NO2   etc.
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• Section II:  Synthesis and biological evaluation of N-(1-((Z)phenyl) 
ethylidene)-1H-pyrazolo[3,4-b]pyridin-3-amine 
 
N
N
N
H
N C
CH3
R
Type (III)   
R = NH2, Cl, OH, CH3 etc.
 
 
 
The Schiff base derivatives of Type (II) and Type (III) have been synthesized by 
mixture of equimolar amount (0.01) of 1H-pyrazolo[3,4-b]pyridin-3-amine (Type I) and 
different aryl aldehydes/acetophenones in the presence of catalytic amount of glacial 
acetic acid in 95% ethanol as a solvent. 
 
 PART-III STUDIES ON THIAZOLIDINONES 
Thiazolidinone are one of the most intensively investigated classes of aromatic 
five membered heterocycles. The derivatives of 4-thiazolidinone nucleus have occupied a 
unique place in the field of medicinal chemistry due to wide range of biological activities 
like antibacterial, antitubercular, anticancer, anticonvulsant and antifungal. 
Thiazolidinone derivatives also find new a variety of applications ranging from 
bacteriostatics, antibiotics, and CNS regulants. All these facts were driving force to 
develop novel Thiazolidinone derivatives with wide structural variation. In continuation 
to the same research topic, we report here some novel substituted Thiazolidinone. We 
have also studied the biological activity of these derivatives. 
 
 
• Section I: Synthesis and biological evaluation of 2-((Z)phenyl)-3-(1H-
prazolo[3,4-b]pyridine-3-yl)thiazolidin-4-one 
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N
N
N
H
N
SO
R
Type (IV)
R = H, OH, Cl, OCH3, NO2 etc.
 
 
The Thiazolidinone derivatives Type (IV) have been synthesized by the reaction 
of Schiff base of Type (II) and mercaptoacetic acid in toluene using a Dean-Stark 
separator. 
 
PART-IV STUDIES ON CHALCONES  
 
The growing potent literature of recent years demostrate that chalcone being a 
very active intermediate through which novel heterocycles with promissing biological 
profile can be designed. A considerable variety of methods are available in literature for 
the synthesis of chalcones. The most convenient method is the one that involves the 
Claisen-Schimidt condensation of equimolar quantities of aryl methyl ketones with 
arylaldehyde in presence of alcoholic alkali. Chalcones have been proved to be an 
important intermediate for the synthesis of many heterocyclic compounds in organic 
chemistry. These facts prompted us to synthesize some new chalcone derivatives. 
 
 
• Section I: Synthesis and biological evaluation of methyl-4-(3-
((Z)phenyl)acryloyl)-3-methylbenzoate 
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O
O
O
CH3
CH3
R
   Type (V)   
R = H, OH, Cl,  OCH3, NO2   etc.
 
The chalcone derivatives of Type (V) have been synthesized by the condensation 
of methyl 4-acetyl-2-methylbenzoate with different aryl aldehydes in the presence of 40% 
alcoholic NaOH. 
 
PART- V STUDIES ON PYRAZOLINES  
Amongst nitrogen containing five membered heterocycles, pyrazolines have 
proved to be the most useful framework for biological activities. Pyrazolines have 
attracted attention of medicinal chemists for both with regard to heterocyclic chemistry 
and the pharmacological activities associated with them. Led by these findings it 
appeared of interest to synthesize newer pyrazoline derivatives. 
 
• Section I : Synthesis and biological evaluation of methyl 4-(4,5-dihydro-5-
((Z)phenyl)-1H-pyrazol-3-yl)-2-methylbenzohydrazide 
 
N
NH
O
NH2
N
H
CH3
   Type (VI)   
R = H, OH, Cl,  OCH3, NO2   etc.
R
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The pyrazoline derivatives of Type (VI) have been synthesized by the reaction of 
chalcones of Type (V) with hydrazine hydrate in 95% ethanol. 
  
PART- VI STUDIES ON ISOXAZOLES  
 
Isoxazole is a five membered heterocyclic compound having two hetero atoms: 
oxygen at position 1 and nitrogen at position 2. Isoxazole derivatives exhibit various 
biological activities such as, Antibacterial, Anticonvulsant, Anticancer, 
Antiinflammatory, Muscle relaxant, Antimicrobial, Antiviral etc. Claisen first reported an 
isoxazole for a product from the reaction of 1,3 diketone with hydroxylamine. It was 
shown to possess typical properties of an aromatic system but under certain  reaction 
conditions. Particularly in reducing or basic media, it becomes very highly labile. With an 
intension of preparing the compounds possessing better therapeutic activity, we have 
under taken the preparation of isoxazoles. 
 
• Section I: Synthesis and biological evaluation of 4-(5-((z)phenyl)isoxazol-3-yl)-
2-methylbenzoic acid 
 
 
 
N
O
O
H
O
CH3
   Type (VII)   
R = H, OH, Cl,  OCH3, NO2   etc.
R
 
 
Isoxazole derivatives of Type (VII) have been prepared by the cyclocondensation 
of chalcone of Type (V) with hydroxylamine hydrochloride in the presence of 40% 
alcoholic KOH. 
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PART- VII  STUDIES ON OXOPYRIMIDINES  
In view of powerful biological activities shown by oxopyrimidines like analgesic, 
antidiabetic, insecticidal, antibacterial etc, it was thought worthwhile to synthesize some 
new oxopyrimidine derivatives possessing better biological active value with least side 
effect. Oxopyrimidines of Type (VIII) have been synthesized by the cyclocondensation of 
chalcones of Type (V) with urea in the presence of basic catalyst. 
 
• Section I: Synthesis and biological evaluation of 4-(6-((z)phenyl)-1,2-
dihydro-2-oxopyrimidin-4-yl)-2-methylbenzoic acid 
 
N
O N
H
OO
H
CH3
R
Type (VIII)   
R = H, OH, Cl,  OCH3, NO2   etc.
 
 
Oxopyrimidines of Type (VIII) have been synthesized by the cyclocondensation 
of chalcones of Type (V) with urea in the presence of basic catalyst. 
 
PART-VIII STUDIES ON PYRIMIDINES  
Pyrimidines are biologically important compounds; their synthesis and chemistry 
have received remarkable attention. Pyrimidine derivatives are found to possess most 
effective therapeutic activities like anti-inflammatory, antiviral, antimalarial, herbicidal 
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etc. These finding prompted us to design and synthesized some pyrimidine derivatives, 
which have been described as under. 
 
• Section I:  Synthesis and biological evaluation of 4-(2-amino-6-((Z) phenyl) 
pyrimidin-4-yl)-2-methyl benzoic acid 
 
N
NH2 N
OO
H
CH3
R
Type (IX)   
R = H, OH, Cl,  OCH3, NO2   etc.
 
 
 Aminopyrimidine derivatives of Type (IX) have been synthesized by the 
condensation of chalcones of Type (V) with guanidine hydrochloride in presence of basic 
media. 
 
• Section II:  Synthesis and biological evaluation of 4-(6-((Z)phenyl)-1,2-
dihydro-2-thioxopyrimidin-4-yl)-2-methylbenzoic acid 
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N
S N
H
OO
H
CH3
R
Type (X)   
R = H, OH, Cl, OCH3, NO2   etc.
 
 
Pyrimidinethione derivatives of Type (X) have been synthesized by the 
cyclocondensation of chalcones of Type (V) with thiourea in presence of basic catalyst. 
 
CHARACTERISATION  
 
The constitution of all above products has been supported by elemental analysis 
and spectral studies like IR, 1H NMR and mass spectroscopy. The purity of the newly 
synthesized compounds was checked by TLC. 
 
IN VITRO STUDY ON MULTIPLE BIOLOGICAL ACTIVITIES  
All the compounds have been evaluated for their antibacterial activity towards 
Gram +ve and Gram -ve bacterial strains and antifungal activity towards fungal strain at 
different concentration. The biological activities of the synthesized compounds have been 
compared with standard drugs. 
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INTRODUCTION 
 
Organic chemists synthesize hundreds of new heterocyclic compounds every 
week. In most cases the chemist has specific reasons for synthesizing a particular 
compound, usually based on theoretical considerations, medicinal chemistry, biological 
mechanisms or a combination of all three. We must always continue to search for drugs 
which exhibit clear advantages over the already existing respective drugs. Such 
advantages may be: (1) A qualitative or quantitative improvement in activity, (2) a partial 
or total absence of undesirable side effects, (3) a lower toxicity, (4) more neutritive value, 
(5) improved stability and (6) a decrease in production cost. 
The last few decades have witnessed massive advances in biochemistry, 
physiology, pharmacology and genetics. This has to a better understanding of working the 
body at the molecular level. This in turn has resulted a much better understanding of the 
structure and function of important drug targets e.g. enzymes and receptors and that how 
drugs can be designed for these targets.  
Any drug must ideally have a broad spectrum of activity, with a rapid bactericidal 
action. Some bacteria produce enzymes that can inactivate or modify antibiotics action. 
Some bacteria produce enzymes that can inactivate or modify antibiotics, and 
insusceptibility of a drug to such degradation or modification could result in its playing an 
important part in therapy. Likewise, some bacteria possess an outer membrane that acts as 
a permeability barrier to the entry of some, but not all, antibiotics. Drugs that can readily 
penetrate this barrier might again be expected to be of possible clinical importance. 
A prerequisite for the design of safe drugs is knowledge about the various 
metabolic reactions that xenobiotics and endogenous compounds undergo in the 
organism. Because pharmacological activity depends on molecular structure, the 
medicinal chemist is restricted in the choice of functional groups for the design of new 
drugs. Often he finds or she encounters a situation where a structure has adequate 
pharmacologic activity but has an inadequate pharmacokinetic profile (i.e., absorption, 
distribution, metabolism and excretion). This is because pharmacology and 
pharmacokinetic departments in the pharmaceutical industry often do not collaborate at 
the early stage of drug development. It is only later, when the new compound is tested in 
animals or in humans, that pharmacokinetic disadvantages become obvious. 
In the pharmaceutical field, this has always been and will continue to be a need for 
new and novel chemical inhibitors of biological function. The current interests in the 
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creation of large, searchable libraries of organic compounds have captured the 
imagination of organic chemist and the drug discovers community. Efforts in numerous 
laboratories focused on the introduction of chemical diversity have been recently 
reviewed and pharmacologically interesting compounds have been identified from 
libraries of widely different composition.  
Important drugs, poisons and medicines (both natural and synthetic) such as 
sulphathiazole, pyrenthrin, rotenmone, alpidem, zolpidem, fluconazole, strychnine, 
reserpine, certain of the antihistamines, the ergot alkaloids caffeine, cocaine, barbiturates, 
etc. are heterocyclic compounds. 
The search for biologically active compounds is the driving force in 
pharmaceutical synthesis. Since the majority of new molecules entering clinical studies 
contains at least one heterocyclic moiety predominantly N-heterocyclic ones[1]. The 
modification of these ring systems plays an important role during drug development[2, 3]. 
Thus, there is always a specific need for novel heterocyclic ring systems, both for finding 
new hit structures and in optimization of lead compounds. Although theoretically 
unlimited, in practical terms and due to technical and economical reasons, only a very 
limited number of heterocycles is available for medicinal chemistry today. 
The heterocyclic compounds are very widely distributed in nature and are very 
essential to living organisms. They play a vital role in the metabolism of all the living 
cells. Among large number of heterocycles found in nature, nitrogen heterocycles are the 
most abundant specially those containing oxygen or sulphur[4] due to their wide 
distribution in nucleic acid illustration and their involvement in almost every 
physiological process of plants and animals. The heterocyclic compounds also occupy 
key position in the area of drugs and pharmaceuticals. Almost 80% of the drugs in clinical 
use are based on heterocyclic constitution because they have specific chemical reactivity. 
Majority of the large number of drugs being introduced in pharmacopeias in recent year 
are heterocyclic compounds. A wide variety of modern drugs such as chlordiazepoxide 
(tranquillizer)[5,6], imipromine (antidepressant)[7], guanethidine (antihypertensive)[8], 
indapamide (diuretic and antihypertensive)[9,10], etc. Many non-steroidal drugs such as 
ketoprofen [11], fenoprofen and flurbiprofen[12] are well known anti-inflammatory agents; 
these derivatives were found to more potent with fewer side effects. Many antibiotics 
including penicillin[13], cephalosporin[14], norfloxacin[15], streptomycin[16,17] etc., also 
contain heterocyclic ring. 
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 Heterocyclic compounds have great applicability in pharmaceutics because they 
have specific chemical reactivity. The majority of synthetic heterocyclic compounds have 
found widespread use, for example as anticancer agents, antitubercular, analeptics, 
analgesic, hypnotics and as pesticides, insecticides and weed killers. Various synthetic 
procedures have been developed and considerable diversity in the ring is achieved. 
Heterocyclic compounds are enormous, their chemistry is complex and synthesizing them 
requires great skill. Advances in organic chemistry have made possible the synthesis of 
complexes molecules. Enantiometry is an important process in medicinal chemistry since 
life is inherently chiral and the drug targets within the body are chiral. As such, they can 
distinguish between the enantiomers of a chiral drug, so the use of recemic drug is 
inherently wasteful, since only one enantiomer is ideally designed to interact with its 
target. Moreover, the existences of the “wrong” enantiomer could create problems if it 
interacted with a different receptor, resulting inside effects. 
The interesting medicinal activities of heterocyclic compounds have stimulated 
considerable research work in recent years leading to the synthetic utility. Taking in a 
view of the applicability of heterocyclic compounds, we have undertaken the preparation 
of heterocycles bearing pyrazolo-pyridine nucleus. The placement of a wide variety of 
substituents of these nuclei has been designed in order to evaluate the synthesized 
products for their pharmacological profile against several strains of bacteria and fungi. 
 The pyrazolo[3,4-b]pyridine system has shown many interesting biological and 
pharmacological properties, such as antitubercular activity[18,19],
 
activity against gram 
positive and negative bacteria[20],
 
and ACTH (Adrenocorticotropic hormone)–releasing 
factor (CRF (Corticotropin-releasing facter)) antagonist activity. CRF antagonists proved 
to be effective in the treatment of a wide variety of stress-related illnesses, such as 
depression, gastrointestinal diseases, anorexia nervosa, haemorrhaged stress, drug and 
alcohol withdrawal symptoms[21] Due to the importance of pyrazolo[3,4-b]pyridines, 
much work has been done over the years. 
 
AIMS AND OBJECTIVES 
In the pharmaceutical field, there has always been and will continue to be a need 
for new and novel chemical entities with diverse biological activities. Our efforts are 
focused on the introduction of chemical diversity in the molecular frame work in order to 
synthesizing pharmacologically interesting compounds of widely different composition. 
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During the course of research work, several entities have been designed, generated 
and characterized using spectral studies. The details are as under. 
? To generate several derivatives like pyrazolo-pyridine, Schiff base, thiazolidinone, 
Chalcones, Pyrazolines, Isoxazolines, OxoPyrimidines, 2-amino Pyrimidines, 
Pyrimidinethiones nucleus. 
? To check the purity of all compounds using thin layer chromatography. 
? To characterize these products for structure elucidation using spectroscopic 
techniques like IR, PMR, Mass spectral and elemental analysis studies. 
? To evaluate these new products for better drug potential against different strains of 
bacteria and fungi. 
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INTRODUCTION 
 
 When pyrazolo and pyridine ring systems are fused together various condensed 
fused systems may arise from such fusion. The pyrazolopridine comprise of five isomers.  
 
N
N
[1,5-a]
(I)
N NH
N
[3,4-b]
(II)
N
N
H
N
[4,3-b]
(III)
N
N
H
N
[3,4-c]
(IV)
N
N
H
N
[4,3-c]
(V)
 
The pyrazolo[3,4-b]pyridine system has shown many interesting biological and 
pharmacological properties, such as antitubercular activity[1,2], activity against gram 
positive and negative bacteria[3]. Interest in the synthesis of condensed pyrazoles has 
recently revived because of the wide variety of their biological properties[4-6]. Although 
the pyrazolo[3,4-b]pyridine ring system has proved to be an interesting class in 
heterocyclic chemistry, it has received little attention in the literature. Some of its 
derivatives are important as anticancer agents with low toxicity[7,8], as anti-
inflammatories[9], as blood platelet aggregation inhibitors[9],as bone metabolism 
improvers[10] as adenosine antagonists[11,12] and as controlling herbicides[13]. They also 
show antifungal and antiparasitic activities[14,15]. In addition, they are used as disperse 
dyes[16] and as fluorescents[17]From all the benefits mentioned above and in continuation 
of our interest directed towards the synthesis of new pyrazine heterocycles[14,15]. 
We would like to report herein a synthesis of new pyrazolo[3,4-b]pyridine 
members along with studies of the effect of some of them as antifungal and as 
antibacterial agents. 
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 However, few publications are devoted to chemistry of pyrazolo[3,4-b] 
pyridines[18] and [19] as indole or indazole isosteres. We report here the synthesis of 3-amino 
pyrazolo[3,4-b]pyridines by cyclisation of 2-chloronicotinonitrile with hydrazines. 
 
SYNTHETIC ASPECT 
 Many polysubstituted derivatives of pyrazolo-[3,4-b]pyridines have been 
synthesized. A recent review describes in detail the chemistry of pyrazolo-[3,4-b]pyridine 
ring system. Pyrazolopyridines have continued to attract interest because of their 
biological activity and structural relationship to indoles and azaindiles [pyrrolopyridines]. 
 Various synthetic approaches have been used to obtain these ring systems, some 
of which are given in the following. 
 
 
1. The most important synthetic method is the condensation of aminopyrazole with 
α,β-unsaturated compounds reported by J. Quiroga.
[20-29] 
 
N
N
Ph
NH2 Ar
1 Ar2
O
ZnCl2
MWI
N
N N
Ph
Ar1
Ar2
 
 
2. S. Abdullah El-Assiery et al.[30]: Synthesis of some new annulated 
pyrazolopyridine derivatives. 
N
N
O
Ar
p-CH3OC6H6H4CHO
CH2(CN)2/CH3COONH4 N
N
N
Ar
Ar'
CN
NH2
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N
N
O
Ar
p-CH3OC6H6H4CHO
N
N
N
Ar
Ar'
CH3
CH3COONH4
CH3COCH2COOC2H5
Ar = 2,4-(NO2)2C6H3
 
 
 
 
THERAPEUTIC IMPORTANCE 
 
Pyrazolo[3,4-b]pyridines are potential bioactive agents due to their wide spectrum 
of therapeutic importance. A large number of substituted Pyrazolo[3,4-b]pyridine 
derivatives are prepared and tested for varieties of biological activities such as, 
 
1. Antitubercular, Antagonist[1,2] 
2. Antiviral[31]
3. Anti-inflammatories[32]
4. Antifungal and Antiparasitic[33,34]
5. Blood platelet aggregation inhibitors[32]
6. Bone metabolism improvers[32]
7. Adenosine antagonists[35,36]  
8. Controlling herbicides[37]
9. Fungicidal[38]
10. Vasodilatory Activities[39]
11. Bactericidal[40] 
 
 
Ashutosh Jamloki et.al.[41] have been synthesized some pyrazolo[3,4-b] 
pyridine(VI) carried out a structural activity relationship study on 6-aryl-pyrazolo[3,4-b] 
pyridine and cited that pyrazolo[3,4-b]pyridine gives many inhibitory activity. 
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N NH
N
R
HN
O
R
(VI)
 
 
Andreas B. J. Parusel et. al.[42] have been studies on Geometries, conformational 
energies and activation barriers for rotations about the single bonds connecting the 
various subunits of a new class of bulky electron donor–acceptor systems derived from 
the bis-pyrazolopyridine chromophore are characterized for several representatives by 
semiempirical methods. 
 
N N
NHHN
N
R
(VII)
 
 Qing Ye et. al.[43] have been prepared series of novel 7-azaindazolyl-indolyl-maleimides 
(VIII) and evaluated for their antiproliferative activity in vitro against various human 
cancer cell lines and protein kinase C inhibitory activity. 
          
1H-Pyrazolo[3,4-b]pyridine…           
Studies on Some Heterocyclic Entities......  
 
20
 
N
N
N
N
N
R2
O
O
(CH2)n
R1
(VIII)
 
 
Thus the important role displayed by Pyrazolo[3,4-b]pyridine and its derivatives 
for various therapeutic and biological activities prompted us to synthesize some Schiff 
bases, Thiazolidinone derivatives bearing pyrazolo[3,4-b]pyridine moiety in order to 
achive compounds having better therapeutic activities. 
 
 
SECTION I 
 
SYNTHESIS AND SPECTRAL STUDIES OF 1H-PYRAZOLO[3,4-b]PYRIDINE-
3-AMINE 
 
REACTION SCHEME 
 
N
CN
Cl
H2N NH2 H2O
Methanol
4 Hrs. Reflux
N NH
N
NH2
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MECHANISM 
The reaction proceeds by way of addition of hydrazine hydrate to 2-chloro-3-cyno 
pyridine in a manner of 1.4-addition (Michael addition) followed by cyclization and 
aromatization. 
Cyclocondensation with 2-chloro-3-cyano pyridine might proceed by two distinct 
pathways in two stages: initial nucleophilic hydrazinodechlorination, followed by 
intramolecular attack by the hydrazine component on the electron-deficient carbon of the 
cyano group, yielding 3-aminopyrazolo[3,4-blpyridines; alternatively, initial reaction may 
be nucleophilic addition of hydrazines to the cyano function, generating an amidrazone 
moiety (-:NH(NH.NH2)) that then intramolecularly displaces the halogen. 
 
N Cl
C N
+ H2N NH2 H2O
.. .
N N
H
C N
N
..
..
H
H
H
+
H+
N NH
N
NH
H
N NH
N
NH2
- HCl
 
The constitution of the synthesized product have been characterized by using 
infrared and 1H-nuclear magnetic resonance spectroscopy and further supported by mass 
spectroscopy.  
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IR SPECTRAL STUDIES OF 1H-PYRAZOLO[3,4-b]PYRIDINE-3-AMINE  
 
 
N NH
N
NH2
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc.) 
 
 
 
Frequency cm-1
Type 
Vibration 
Mode Observed Reported 
Ref. 
 
Aromatic 
 
C-H str. 
C=C str. 
C-H i.p. def. 
C-H o.o.p. def. 
3070 
1524 
1063 
809 
3100-3000 
1585-1480 
1125-1090 
860-810 
44 
” 
” 
” 
Amine 
N=C str. 
C-N str. 
N-H str. 
N-H def. 
1613 
1295 
3422 
1613 
1650-1580 
1350-1200 
3450-3380 
1650-1580 
” 
” 
” 
” 
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1HNMR SPECTRAL STUDIES OF 1H-PYRAZOLO[3,4-b] PYRIDINE-3-AMINE  
 
 
 
Internal Standard: TMS; Solvent: CDCl3 + DMSO: Instrument: BRUKER 
Spectrometer (300 MHz) 
 
 
 
Signal 
No. 
Signal 
 Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
7.00-7.04 
7.94-7.97 
8.46-8.47 
4.19-4.25 
1H 
1H 
1H 
2H 
multiplet 
doublet 
doublet 
singlet 
Ar-H(b) 
Ar-H(c) (J=7.8 Hz) 
Ar-H(a)(J=3.6 Hz) 
Ar-NH2
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EXPANDED AROMATIC REGION 
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EXPERIMENTAL 
 
[A] SYNTHESIS OF 1H-PYRAZOLO[3,4-b]PYRIDINE-3-AMINE 
A solution of 2-chloro-3-cyno pyridine (0.01 mol, 1.38 gm) in hot methanol (15.0 
ml) is prepared in a three-necked round-bottom flask fitted with a stirrer at room 
temperature, drop wise added hydrazine hydrate (2.5 eq., 1.25 gm) over a period of 5 
minutes, stirr the reaction mass for 30 min at room temperature and reflux for 4.0 hrs in 
water bath. Completion of reaction was checked by TLC using mobile phase 
Ethylacetate:Hexane (4:6) ml. After completion of the reaction cool the reaction mass, the 
crude product was isolated and crystallized from absolute ethanol. Yield 91%, M.P. 
1780C. 
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INTRODUCTION 
 
There is always need for the safer antibacterial agents and research efforts are 
going on for developing safer antibacterial agents. Schiff base approach is one of the most 
promising amongst these[1]. In recent years, there has been an increasing interest in the 
design and development of Schiff base derivatives Schiff base are associated with 
antibacterial, antifungal and antitubercular activities and have diverse biological 
activities[2].  
 General account of the summary of reaction of aldehydes with amine (aromatic or 
aliphatic) has been reviewed by Murray[3]. Some Schiff bases from 2-hydroxy 
benzaldehyde and 3-hydroxy-4-pyridine-carboxaldehyde with various amines were also 
synthesized and the effect of substituent on Ketoenol equilibria[4] and hydrogen bonds[5] 
have also been reported. Some other Schiff bases have also been synthesized from 
salicyaldehydes with aromatic amines and aliphatic amines and their characterizations 
were done by using IR, NMR and mass spectra[6-9]. Dayagi and Degani[10] have reported 
some methods for the synthesis of Schiff bases. Sampat et al.[11] gave the detail study 
report on heterocyclic Schiff bases ligands by condensing pyrrole 2-carboxaldehyde and 
pyridine 2-carboxaldehyde with aromatic amines. Singh et al.[12] had synthesized Schiff 
bases derived from 4-amino antipyrine and studied their IR and thermal properties. A 
series of new thorium (IV) complexes with a Schiff bases derived from fluoroaniline and 
p-(N, N’-dicyanoethyl) amino benzaldehyde have been synthesized by Goyal et al.[13] 
Chang and Pan reported some Schiff bases derived from amino phenols and aromatic 
aldehydes[14]. A new one pot procedure for the generation of azomethine via 
chlorominium salt has been investigated by 
Anderson and co-workers[15]. Amanda J. Gallant et al.[16] have preparedSchiff base by 
condensation of equimolar quantity of 3,6 diformyl catechol and substituted o-
phenylenediamine. Pierre L. Beaulieu et al.[17] have synthesized (E)-N-phenyl 
methyleneglycineethyl ester by the cyclocondensation of glycine ethyl ester 
hydrochloride, t-butylmethyl ether (TBME), benzaldehyde was added followed by 
anhydrous Na2SO4 and triethylamine. 
Schiff bases are known to be useful in perfumery [18,19] as corrosion inhibitor[20,21] 
as complexing agents[22-24] and as intermediate in many reactions[25-29]. They are used in 
optical and electrochemical sensors, as well as in various chromatographic methods, to 
enable detection of enhance selectivity and sensitivity[30-32]. In literature, some other 
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applications of Schiff bases have also been reported in various fields [33-37]. Some of these 
compounds and their metal complexes have also been used in the preparation of various 
medicines[38-42]. Further, many workers[43-50] reported a wide range of biological activities 
of various Schiff bases. Besides, several Schiff bases have been reported to possess 
remarkable antibacterial[51-55], antifungal[56-61], anticancer[62-66], anti HIV[67-69], anti-
inflammatory[70-73], antiparasitic[74,75] and diuretic[76] activities. 
 
SYNTHETIC ASPECT 
 
1. General account of the summary of reaction of aldehydes with amine (aromatic or 
aliphatic) has been reviewed by Murray[77] 
 
R CHO + R' NH2 R CH
N R' + H2O
 
 
2. Amanda J. Gallant et al.[78] have prepared schiff bases by the condensa- tion of 
equimolar quantity of 3, 6 diformyl catechol and substituted o-phenylenediamine. 
 
OH
OH
O
O
H2N
NH2
OR
OR
OH
OH
O
NH2
OR
OR
N+
 
 
3. Oddo and Tognacchini[79] have introduced the comparative rates of formation of 
Schiff’s base from aniline, substituted aniline and aromatic aldehydes using a 
cryscopic method follow the course of reaction. 
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MECHANISM 
The condensation takes place in two steps. The first is marked by the formation of 
an addition compound (an amino-alcohol). In second step one molecule of water from the 
addition product splits off. The mechanism is given bellow.  
 
N NH
N
NH2
..
+ R C
H
O
N NH
N
+H2N CH
O-
R
N NH
N
N CH
OH
R
H
H2O-
N NH
N
N
H
C
R
 
 
THERAPEUTIC IMPORTANCE 
Schiff bases exhibit a wide range of pharmacological activities like antifungual, 
antibacterial, antiviral, antiinflammatory etc. Pandey Taruna et al..[80] prepared 
azomethines and their boron complexes and screened for their antifungal and antibacterial 
properties. It is evident that azomethines alone were quite toxic but their activity 
increased after complexation. Omar et al.[81] have determined cyclocondensation of 
azomethines having good antischistosomal activity. Praveen M. and co-workers[82] have 
synthesized a novel class of acetyl ferrocene derived from Schiff bases having 
antimicrobial activity. 
Ram Tilak et al.[83] have synthesized some Schiff’s bases, thiazolidinones 4-
triazolines, and formazones of 2-chloro phenothiazines and screened against 
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carrageenininduced edema in albino rats. The thiazolidinones showed promising anti-
inflammatory activity. 
Ravindra V. Chambhare et al.[84] have prepared some azomethines and tested for 
their antimicrobial activity. B. Shivarama Holla et. al.[85] have synthesized azomethines of 
(I) having antibacterial and anti-inflammatory activity. 
Cl
Cl
Cl
S
N
H
N
N O R
(I)
R = 2-NO2, 4-NO2,4-Br etc.
 
Pawar R. P. et al[86] have synthesized azomethines by the condensation of 
iodovanillin with different substituted aromatic amines and tested for antibacterial 
activity. Ergenc and co-workers[87] have synthesised azomethine derivatives having 
antifungal activity. Yadav Bodke[88] have synthesized some azomethines and tested for 
their biological activity. B. Shivarama Holla et al.[89] have prepared and reported 
anticancer activity of some new Schiff bases. 
Mehta R. H. et al.[90] have synthesized coummarin schiff’s base derivatives of (II) 
and examined for their antibacterial activity. Khalafallah A. K. and Hassan M. E.[91] have 
prepared some styryl Schiff’s bases spiro derivatives as potential antibacterial and 
antifungal activity. Sharaf El-Din, and Nabaweyal[92] have synthesized some azomethine 
derivatives (III) having good antibacterial activity. 
 
O
N
O N
OH
Me
R
(II)
(III)
R=Ph, 4-Br-C6H4,4-NO2-C6H4
     2-Cl-C6H4CONH
R=3,4-OH, 3,4-NO2
     3,4-(OMe)2
R
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Cascaval Alexandru et al.[93] have synthesized azomethines, which have good 
analgesic and antipyretic properties. Pandeya S. N. et al.[94] have synthesized Schiff bases 
showed good activity against Vibrio cholerae non-o., Shigella boydii, Enterococcus 
faecalis and Edwaredsiella torla with MIC in the rang of 10-25 μg/ml. Some compounds 
were found to be active against Salmonellal typhi and Vibro cholerae-0, MIC 25-150 
μg/ml). 
Ali Yousif et al.[95] have synthesized some Schiff’s base derivatives of glucose 
containing acetylenic bond and tested for their bactericidal activity against E. coli and 
Staphylococcus aureus. 
S. J. Wadher et al.[96] have synthesized some schiff’s base derivatives of Para 
amino salicylic acid tested  for their antibacterial activity against the E. coli, S. aureus, 
and ntifungal activity of compounds was studied against C. albicans and A. niger 
according to cup-plate method. The synthesised compound found to have better 
antimicrobial activity than the parent compound. 
 
NH2
HO
O
HO
R
O
H N
HO
O
HO
R
+
 
 
Iana Vazzana et. al.[97] described sets of Schiff bases (IV) and (V) (diaryl- and 
arylheteroaryl azomethines) endowed with strong and long lasting antiinflammatory 
activity against the rat hind paw edema induced by carrageenan. 
 
N
C
H
N
CF3
C
H
NS
O
O
H2N F
(IV) (V)
 
Vijay Kumar.M.M.J.et. al.[98]have synthesized some new Schiff bases (VI) 
containing different functional groups and check antimicrobial activity against gram-
positive and gram-negative bacteria. 
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N
C
O
HN
N
N
H
Cl
F
HC
OCH3
HO
(VI)
 
Gundibasappa K. Nagaraja et. al.[99] have been  synthesized some Schiff bases 
(VII)  and screened for their antibacterial and antifungal activities. 
O
HN
O
N N
Cl
R3 R2
R1
R
(VII)
 
Looking to the interesting properties of azomethines, we have synthesized some 
new azomethines, which have been described as under. 
 
 
SECTION I: SYNTHESIS AND BIOLOGICAL EVALUATION OF N-((Z) 
BENZYLIDINE)-1H-PYRAZOLO[3,4-b]PYRIDINE-3-AMINE 
 
SECTION II: SYNTHESIS AND BIOLOGICAL EVALUATION OF (Z)-N-(1-((Z) 
PHENYL)ETHYLIDENE)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-
AMINE 
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SECTION I  
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF N-((Z)BENZYLIDINE)-1H-
PYRAZOLO[3,4-b]PYRIDINE-3-AMINE 
Looking to the interesting properties of azomethines, with an intension to 
synthesizing better therapeutic agents, azomethine derivatives of Type (II) have been 
synthesized by the condensation of 1H-Pyrazolo[3,4-b]Pyridine-3-amine with different 
aromatic aldehydes in order to study their biodynamic behavior. 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further 
supported by mass spectroscopy.  
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
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REACTION SCHEME 
 
N
N
N
H
NH2
OHC
N
N
N
H
N
R
R
8.0 Hrs., Reflux
Ethanol
+
(Type II)
gl. CH3COOH
Type (I)
R = OH, Cl, NO2, N(CH3)2,OCH3 etc.
 
 
 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
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IR SPECTRAL STUDIES OF 2-[(1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL-
IMINO)METHYL]PHENOL 
 
N NH
N
N C
H
HO
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc.) 
 
 
Frequency cm-1
Type 
Vibration 
Mode Observed Reported 
Ref. 
 
Alkane 
 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
2918  
2850 
1429 
1348 
2975-2920 
2880-2860 
1470-1435 
1395-1370 
100 
” 
” 
” 
 
Aromatic 
 
C-H str. 
C=C 
C-H i.p. def. 
C-H o.o.p. def. 
3012 
1537 
1099 
821 
3100-3000 
1585-1480 
1125-1090 
860-810 
” 
” 
” 
” 
Azomethine 
N=C str. 
C-N str. 
1589 
1259 
1650-1580 
1350-1200 
” 
” 
Hydroxy 
O-H str. 
O-H def. 
3219 
1309 
3650-2590 
1410-1310 
” 
” 
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1HNMR SPECTRAL STUDIES OF 2-[(1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL-
IMINO)METHYL]PHENOL 
 
 
 
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer 
(300MHz) 
 
Signal 
No. 
Signal Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
5 
6.94-7.02 
7.35-7.48 
8.71 
11.39 
13.01 
4H 
3H 
1H 
1H 
1H 
multiplet 
multiplet 
singlet 
singlet 
singlet 
Ar-H(b,e,f,g) 
Ar-H(a,c,d) 
-CH(h) 
Ar-OH 
-NH 
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EXPANDED AROMATIC REGION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF N-((Z)BENZYLIDINE)-1H-
PYRAZOLO[3,4-b]PYRIDINE-3-AMINE 
 
 [A] SYNTHESIS OF 1H-PYRAZOLO[3,4-b]PYRIDINE-3-AMINE 
 
 See, Part-I, Experimental [A]. 
 
[B] SYNTHESIS OF 2-[(1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL-IMINO) 
METHYL]PHENOL 
A mixture of 1H-Pyrazolo[3,4-b]pyridine-3-amine (0.01 mol, 1.34 gm) and 2-
hydroxy benzaldehydes (0.01 mol, 1.22 gm) was taken in ethanol (25.0 ml) using 
catalytic amount of gla. acetic acid. The reaction mixture was refluxed for 8.0-10 hrs on 
waterbath. The product was isolated and crystallized from absolute ethanol. Yield 90%; 
m.p.1920C. 
 Similarly other Synthesis of N-((Z)benzylidine)-1H-pyrazolo[3,4-b]pyridine-3-
amine were obtained. Various physical constants for all the synthesized compounds are 
given in Table 1. 
 
[C] BIOLOGICAL EVALUATION OF N-((Z)BENZYLIDINE)-1H-
PYRAZOLO[3,4-b]PYRIDINE-3-AMINE 
 
? DETERMINATION OF MINIMAL INHIBITION CONCENTRATIONS BY 
BROTH DILUTION METHOD 
? MATERIALS AND METHOD  
1. All the Synthesized Drugs Were Used For Antibacterial Test Procedures 
2. All Necessary Controls Like: 
? Drug Control 
? Vehicle Control 
? Agar Control 
? Organism Control 
? Known Antibacterial Drugs Control 
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? All MTCC Cultures Were Tested Against Above Mentioned Known and 
Unknown Drugs. 
? Mueller Hinton Broth Was Used as Nutrient Medium to Grow and Dilute the 
Drug Suspension for the Test bacteria. 
? Inoculum Size for Test Strain Was Adjust to 108 Cfu [Colony Forming Unit] per 
milliliter by comparing the turbidity. 
? Following common standard strains were used for screening of antibacterial and 
antifungal activities: The strains were procured from Institute of Microbial 
Technology, Chandigarh. 
E.COLI KL.PNEUMONIAE S.AUREUS S.PYOGENUS 
MTCC 442 MTCC 4030 MTCC 96 MTCC 443 
 
? DMSO was used as diluents / vehicle to get desired concentration of drugs to test 
upon standard bacterial strains. 
 
? MINIMAL INHIBITION CONCENTRATION [MIC]: 
  The main advantage of the ‘Broth Dilution Method’ for MIC determination lies 
in the fact that it can readily be converted to determine the MIC as well. 
1. Serial dilutions were prepared in primary and secondary screening. 
2. The control tube containing no antibiotic is immediately sub cultured [before 
inoculation] by spreading a loopful evenly over a quarter of p[late of medium 
suitable for the growth of the test organism and put for incubation at 370C  
overnight. The tubes are then incubated overnight. 
3. The MIC of the control organism is read to check the accuracy of the drug 
concentrations.  
4. The lowest concentration inhibiting growth of the organism is recorded as the 
MIC.  
5. The amount of growth from the control tube before incubation [which represents 
the original inoculum] is compared.  
? METHODS USED FOR PRIMARY AND SECONDARY SCREENING: 
Each synthesized drug was diluted obtaining 2000 microgram /ml concentration, 
as a stock solution. 
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PRIMARY SCREEN:     
In primary screening 1000 micro/ml, 500 micro/ml, and 250 micro/ml 
concentrations of the synthesized drugs were taken. The active synthesized drugs found in 
this primary screening were further tested in a second set of dilution against all 
microorganisms. 
SECONDARY SCREEN:   
The drugs found active in primary screening were similarly diluted to obtain 200 
micro/ml 100 micro/ml, 50 micro/ml, 25 micro/ml, 12.5 micro/ml, 6.250 micro/ml, and 
concentrations.  
READING RESULT:      
The highest dilution showing at least 99 % inhibition zone is taken as MIC. The 
result of this is much affected by the size of the inoculum. The test mixture should 
contain 108 organism/ml.      
The antimicrobial activity was compared with standard drug viz Ampicillin, 
Ciprofloxacin, Gentamycin, Chloramphenicol, Norfloxacin and antifungal activity was 
compared with Nystatin Greseofulvin. Results of test solutions are recorded in Table 2. 
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TABLE 2: BIOLOGICAL EVALUATION OF N-((Z)BENZYLIDINE)-1H-
PYRAZOLO[3,4-b] PYRIDINE-3-AMINE 
 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml 
Gram +ve Bacteria Gram –ve Bacteria 
 
Minimal fungicidal concentration 
μg/ml Sr. No. Code  
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1 1a 250 250 200 1000 500 1000 1000 
2 1b 1000 500 250 250 500 1000 1000 
3 1c 200 200 100 200 500 500 500 
4 1d 100 100 1000 250 250 500 500 
5 1e 200 200 250 500 1000 500 500 
6 1f 250 250 62.5 100 200 500 500 
7 1g 500 1000 100 200 500 >1000 >1000 
8 1h 200 200 200 250 250 500 500 
9 1i 100 100 1000 500 1000 250 250 
10 1j 1000 250 500 1000 500 >1000 >1000 
11 1k 100 250 100 250 500 250 1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
E.coli P.aeruginosa S.aureus S.pyogenus 
Standard Drugs 
(microgramme/ml) 
Gentamycin 0.05 1 0.25 0.5 
Ampicillin 100 100 250 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 25 25 50 50 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
C.Albicans A.Niger A.Clavatus 
Standard Drugs 
(microgramme/ml) 
 Nystatin 100 100 100 
Greseofulvin 500 100 100 
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ANTIBACTERIAL ACTIVITY:  
From screening results, substituted schiff base  1f (R = -4-Cl) possesses very good 
activity against E. coli compared with ampicillin while 1d (R = -4-N,N(CH3)2) and 1i (R= 
-4-OCH3) against S.aureus and S.pyogenus, 1c (R= -4-OH) and 1g (R= -4-NO2) against 
E-coli, 1k (R= -4-F) against S.aureus and E-coli possesses moderate activity compared 
with ampicillin. The remaining schiff bases possess poor to very poor activity against all 
four bacterial species.  
 
ANTIFUNGAL ACTIVITY: 
 
Antifungal screening data showed that substituted schiff bases 1f (R = -4-Cl) against 
C. albicans show highly promising activity compare with standard drug while 1d (R = -4-
N,N(CH3)2 , and 1h (R = H) against C. albicans, 1k (R = -4-F) against A.niger while 1i (R = -
4-OCH3) against A.niger and A.clavatus shows very good activity compare with standard 
drug. The remaining compounds exhibited only moderate to poor activity. 
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SECTION II 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF (E)-N-(1-((Z)PHENYL) 
ETHYLIDENE)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-AMINE 
Schiff base play a vital role owing of their wide range of biological activity and 
with an aim to getting better drug, it was considered worthwhile to synthesize some 
azomethine derivatives of Type (III) by the condensation of 1H-Pyrazolo[3,4-b]Pyridine-
3-amine Type (I) with different aromatic acetophenones in order to study their 
biodynamic behavior. 
 
REACTION SCHEME 
N
N
N
H
NH2
O
CH3
N
N
N
H
N
CH3
R
R
12.0 Hrs., Reflux
Ethanol
+
(Type III)
gl. CH3COOH
R = OH, Cl, NH2, CH3, OCH3 etc.
(Type I)
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The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further 
supported by mass spectroscopy.  
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
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IR SPECTRAL STUDIES OF 2-((E)-1-(1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL -
IMINO)ETHYL)PHENOL 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc.) 
 
Frequency cm-1
Type 
N NH
N
N C
CH3
HO
Vibration 
Mode Observed Reported 
Ref. 
Alkane 
(Methane) 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
3022 
2875 
1467  
1388 
2975-2920 
2880-2860 
1470-1435 
1395-1370 
100 
” 
” 
” 
 
Aromatic 
 
C-H str. 
C=C 
C-H i.p. def. 
C-H o.o.p. def. 
3091 
1539 
1157 
846 
3100-3000 
1585-1480 
1125-1090 
860-810 
” 
” 
” 
” 
Azomethine 
N=C str. 
C-N str. 
1666 
1284 
1650-1580 
1350-1200 
” 
” 
O-H str. 3414 3650-2590 ” 
” 
Hydroxy 
O-H def. 1346 1410-1310 
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1H NMR SPECTRAL STUDIES OF 2-((E)-1-(1H-PYRAZOLO[3,4-b]PYRIDIN-3-
YLIMINO)ETHYL)PHENOL 
 
 
 
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer (400 
MHz) 
 
 
Signal 
No. 
Signal Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
2.58 
6.92-6.96 
7.02-7.04 
7.35-7.40 
7.63-7.66 
13.26 
3H 
3H 
1H 
2H 
1H 
1H 
singlet 
multiplet 
-CH3 
Ar-H(e,f,g) 
doublet Ar-H(b)(J=8.0 Hz) 
multiplet Ar-H(c,d) 
multiplet Ar-H(a) 
singlet -NH 
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EXPANDED REGION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF N-(1-
((Z)PHENYL)ETHYLIDENE)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-AMINE 
 
[A] SYNTHESIS OF 1H-PYRAZOLO[3,4-b]PYRIDINE-3-AMINE 
 
 See, Part-I Experimental [A]. 
 
[B] SYNTHESIS OF N-(1-(2-HYDROXYPHENYL)ETHYLIDENE)-1H-
PYRAZOLO[3,4-b]PYRIDIN-3-AMINE 
 
A mixture of 1H-Pyrazolo[3,4-b]pyridine-3-amine (0.01 mol, 1.34 gm) and 2-
hydroxy acetophenone (0.01 mol, 1.36 gm) was taken in ethanol using catalytic amount 
of gla. acetic acid. The reaction mixture was refluxed for 12 hrs. The product was isolated 
and crystallized from absolute ethanol. Yield 87%; m.p.2020C. 
Similarly other N-(1-((Z)phenyl)ethylidene)-1H-pyrazolo[3,4-b]pyridin-3-amine 
were obtained. Various physical constants for all the synthesized compounds are given in 
Table 3. 
 
[C] BIOLOGICAL EVALUATION OF N-(1-((Z)PHENYL)ETHYLIDENE)-1H-
PYRAZOLO [3,4-b]PYRIDIN-3-AMINE 
 
Antimicrobial testing were carried out as described in Experimental Section-I [C]. 
The results of test solutions are recorded in Table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Schiff Bases… 
Studies on Some Heterocyclic Entities...... 
 
56
 
   
Sr
.  
   
   
   
   
   
  R
   
   
   
   
   
   
   
 M
ol
ec
ul
ar
   
   
   
   
   
M
ol
ec
ul
ar
   
   
M
.P
.  
   
Y
ie
ld
   
   
   
   
%
 o
f N
itr
og
en
   
   
   
R
f  
   
   
   
   
So
lv
en
t  
   
   
   
   
  
    
N
o.
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 F
or
m
ul
a 
   
   
   
   
   
  W
ei
gh
t  
   
   
   
 0 C
   
   
   
   
%
   
   
  C
al
cd
.  
   
  F
ou
nd
   
   
 V
al
ue
   
   
   
 S
ys
te
m
 
   
  2
d 
   
   
   
4-
M
et
hy
l  
   
   
   
   
   
   
C
15
H
14
N
4 
   
   
   
   
   
 2
50
.3
0 
   
   
   
   
15
0 
   
   
   
85
   
   
   
 2
2.
38
   
   
   
22
.4
1 
   
   
   
 0
.6
2 
   
   
   
   
  S
1 
   
  2
e 
   
   
   
4-
N
itr
o 
   
   
   
   
   
   
   
  C
14
H
11
N
5O
2  
   
   
   
 2
81
.2
7 
   
   
   
   
29
5 
   
   
  7
0 
   
   
   
 2
4.
90
   
   
   
24
.9
2 
   
   
   
 0
.5
2 
   
   
   
   
  S
1
   
  2
f  
   
   
  4
-C
hl
or
o 
   
   
   
   
   
   
  C
14
H
11
C
lN
4  
   
   
   
  2
70
.7
2 
   
   
   
   
24
1 
   
   
  7
8 
   
   
   
 2
0.
70
   
   
   
20
.6
9 
   
   
   
 0
.5
0 
   
   
   
   
  S
1
   
  2
g 
   
   
  4
-F
lu
or
o 
   
   
   
   
   
   
   
C
14
H
11
FN
4  
   
   
   
   
25
4.
26
   
   
   
   
 2
32
   
   
   
 9
0 
   
   
   
 2
2.
04
   
   
   
22
.0
0 
   
   
   
0.
49
   
   
   
   
   
S 1
   
  2
h 
   
   
  H
   
   
   
   
   
   
   
   
   
   
   
C
14
H
12
N
4  
   
   
   
   
  2
36
.2
7 
   
   
   
   
16
5 
   
   
   
76
   
   
   
  2
3.
71
   
   
   
23
.7
2 
   
   
   
 0
.5
7 
   
   
   
   
  S
1  
    
 1
   
   
   
   
   
   
  2
   
   
   
   
   
   
   
   
   
  3
   
   
   
   
   
   
   
   
   
  4
   
   
   
   
   
   
 5
   
   
   
   
 6
   
   
   
   
   
 7
   
   
   
   
   
8 
   
   
   
   
   
 9
   
   
   
   
   
  1
0 
   
  2
a 
   
   
   
2-
H
yd
ro
xy
   
   
   
   
   
  C
14
H
12
N
4O
   
   
   
   
   
25
2.
27
   
   
   
   
20
2 
   
   
   
87
   
   
   
 2
2.
21
   
   
   
22
.2
0 
   
   
   
 0
.4
6 
   
   
   
   
  S
1
   
  2
b 
   
   
   
4-
H
yd
ro
xy
   
   
   
   
   
  C
14
H
12
N
4O
   
   
   
   
   
25
2.
27
   
   
   
   
22
0 
   
   
   
68
   
   
   
 2
2.
21
   
   
   
22
.2
3 
   
   
   
 0
.4
8 
   
   
   
   
  S
1
   
  2
i  
   
   
  4
-M
et
ho
xy
   
   
   
   
   
   
C
15
H
14
N
4O
   
   
   
   
 2
66
.3
0 
   
   
   
   
18
0 
   
   
   
91
   
   
   
  2
1.
04
   
   
   
21
.0
3 
   
   
   
 0
.5
1 
   
   
   
   
  S
1
   
  2
j  
   
   
  2
-C
hl
or
o 
   
   
   
   
   
   
  C
14
H
11
C
lN
4  
   
   
   
  2
70
.7
2 
   
   
   
  1
92
   
   
   
 8
3 
   
   
   
 2
0.
70
   
   
   
20
.7
5 
   
   
   
 0
.5
3 
   
   
   
   
  S
1
   
  2
c 
   
   
   
4-
A
m
in
o 
   
   
   
   
   
   
  C
14
H
13
N
5  
   
   
   
   
   
25
1.
29
   
   
   
   
19
8 
   
   
   
60
   
   
   
 2
7.
87
   
   
   
27
.8
5 
   
   
   
 0
.4
0 
   
   
   
   
  S
1
T
A
B
L
E
 3
: P
H
Y
SI
C
A
L
 C
O
N
ST
A
N
T
S 
N
-(1
-((
Z
)P
H
E
N
Y
L
)E
T
H
Y
L
ID
E
N
E
)-1
H
-P
Y
R
A
Z
O
L
O
 [3
,4
-b
]P
Y
R
ID
IN
-3
-A
M
IN
E
 
S 1
-H
ex
an
e 
: E
th
yl
ac
et
at
e-
 7
 : 
3 
 
 Schiff Bases… 
Studies on Some Heterocyclic Entities...... 
 
57
TABLE 4: BIOLOGICAL EVALUATION OF N-(1-((Z)PHENYL) 
ETHYLIDENE)-1H-PYRAZOLO [3,4-b]PYRIDIN-3-AMINE 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml 
Gram +ve Bacteria Gram –ve Bacteria 
Minimal fungicidal concentration 
μg/ml Sr. 
No. Code  
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1 2a   100 1000 250 500 1000 200 200 
2 2b 250 500 100 100 200 500 500 
3 2c 250 250 200 200 250 1000 250 
4 2d 200 1000 250 1000 >1000 >1000 >1000 
5 2e 1000 100 250 200 500 500 200 
6 2f 200 62.5 1000 100 200 250 500 
7 2g 500 250 62.5 1000 500 >1000 1000 
8 2h 200 200 100 100 1000 250 200 
9 2i 1000 100 500 1000 1000 250 250 
10 2j 100 200 250 200 250 500 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
E.coli P.aeruginosa S.aureus S.pyogenus 
Standard Drugs 
(microgramme/ml) 
Gentamycin 0.05 1 0.25 0.5 
Ampicillin 100 100 250 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 25 25 50 50 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
C.Albicans A.Niger A.Clavatus 
Standard Drugs 
(microgramme/ml) 
 Nystatin 100 100 100 
Greseofulvin 500 100 100 
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ANTIBACTERIAL ACTIVITY:  
 From screening results, substituted Schiff base 2f (R= -4-Cl) against S.pyogenus 
while 2g (R= -4-F) against E-coli possesses excellent activity as compared with 
ampicillin. 2a (R= -2-OH) and 2j (R= -2-Cl) against S.aureus, 2e (R= -4-NO2) against 
S.pyogenus,  2b (R= -4-OH) and 2f (R= -4-Cl) against E-coli, 2b (R= -4-OH) and 2h (R= 
-H) against P.aeruginosa possesses good activity against E-coli, The  remaining schiff 
bases possesses moderate to poor activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY: 
 
Antifungal screening data showed that substituted schiff bases 2b (R= -4-OH) and 
2f (R = -4-Cl) against C.albicans, 2a (R = -2-OH) against A.niger, 2e (R = -4-NO2) 
against A.clavatus shows highly promising activity compare with standard drug. 2c (R = -
4-NH2) and 2j (R= -2-Cl) against C.albicans, 2c (R = -4-NH2) and 2f (R = -4-Cl) against 
A.niger while 2i (R = -4-OCH3) against A.clavatus possesses good activity compare to 
standard drug. The remaining compounds exhibited only moderate to poor activity. 
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INTRODUCTION 
 
4-Thiazolidinones play a vital role due to their wide range of biological activities 
and industrial importance. 4-Thiazolidinones are always being an attraction point for 
researchers because of its efficiency towards various pharmacological usages. The 
enhanced prevalence of infectious diseases threatens world population. Although 
tuberculosis appeared as a curable disease for years, it is regaining importance due to the 
multidrug resistance
[1,2]
. Worldwide statistics on tuberculosis surprisingly reveals that, 
nearly one–third of the world’s population is infected with tuberculosis, with 
approximately eight million new patients every year. A major issue is the increase of 
multi-drug resistant tuberculosis (MDRTB) giving rise to the disease expensive and 
incurable especially in immunod eficient subjects such as AIDS patients. Hence, there is 
an increased demand to develop new antituberculosis agents effective against pathogens 
resistant to current treatment. 
The derivatives of 4-thiazolidinone nucleus have occupied a unique place in the 
field of medicinal chemistry due to wide range of biological activities like antibacterial, 
antitubercular, anticancer, anticonvulsant and antifungal
[3]
. They have interesting activity 
profiles mainly cox-1 inhibitors, inhibitors of bacterial enzyme, non nucleoside inhibitors 
of HIVRT and antihistaminic agents
[4]
. 4-thiazolidinones are derivatives of 
thiazolidinone with carbonyl group at the 4
th
 position and formed by the attack of sulphur 
nucleophile on imine carbon followed by intramolecular cyclisation with elimination of 
water. 
Recent studies on molecular modification of the latter (TBZs) revealed that, 
dismantling of the imidazole nucleus leading to the design of new 1,3-thiazolidin-4-one 
derivatives, maintained the molecular requirements for enzyme inhibition
[5]
. A literature 
search revealed that, 4–thiazolidinone derivatives may exhibit antibacterial[6,7], 
antituberculosis
[8-10]
, antiviral
[12,5,11-16]
 and anticancer
[17-20]
 properties. According to 
Andres et al.
[6]
, 4-thiazolidinones may be considered as phosphate bioisosteres and 
therefore inhibit the bacterial enzyme MurB which is involved in the biosynthesis of 
peptidoglycan layer of the cell wall
[6]
. In addition, some thiazolidinones were recently 
reported as novel inhibitors of mycobacterial rhamnose synthetic enzymes
[21]
. This new 
approach is believed to be selective as rhamnose which is not found in humans, has been 
shown to be essential for mycobacterial cell wall synthesis
[21]
. 
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SYNTHETIC ASPECTS 
Synthesis of 4-thiazolidinones has been reported either by cyclisation of acyclic 
compounds or by interconversion among appropriately substituted 
thiazolidinone derivatives.  
1. R. A. Mane
[22]
 and co-workers have synthesised 4-thiazolidinone bearing 2-
mercapto-4-methylimidazoles moiety. 
2. Mogilaiah et al.
[23]
 have synthesized 2-aryl-3-(2-trifluromethyl-1,8-
naphthyridine-3-carbonylamino)-4-thiazolidinones. 
3. Synthesis of 4-thiazolidinones has been reported by the microwave 
irradiation
[24,25] 
4. Parikh et al. have synthesised variety of 4-thiazolidinones bearing diphenyl 
sulphone
[26]
, substituted aryl
[27,28]
 arsanilic acid
[29]
, 2-aryl-1,3,4-thiadiazole
[30]
,γ-
picolinylamino
[31]
, s-triazine
[32]
, benzoylamino acetamido
[33]
, sulphonamido 
benzoylamino
[34]
, phthalazine-1-yl-amino
[35]
, aryl substituted hydroxyaryl, β-β-
dichloroethylaminophenyl and 8-hydroxyquinolinyl moieties of 4-thiazolidinone 
ring system (V) have been reported as potent antimicrobial agents. 
 
 
MECHANISM 
The cyclocondensation proceeds by the attack of the mercaptoacetic acid upon 
the C=N group. The HSCH2COOH adding to the carbon atom followed by the 
cyclisation. 
R' N C
H
+
OH
SH
O
R' N C R
OH
S
O
H2O-
N CH
R
S
O
R'R
. 
Sometimes, the uncyclised product in these reaction has been isolated
[36]
. 
Phosphorous pentoxide in dioxan was used for subsequent cyclisation of certain 
uncyclised products
[37]
. The nucleophillic attack of thioglycolic anion on carbon of 
azomethine having positive character and nitrogen having negative character is 
Studies on Some Heterocyclic Entities...... 
 
 
4-Thiazolidinone… 
66 
evidenced
[38]
. Simultaneously, the removal of water take place is rate determining step 
and helps in cyclisation. 
 
THERAPEUTIC EVALUATION 
The thiazolidinone derivatives substituted at 2- and 3-position are associated with 
diverse biological activities which have been reported as under. 
1. Antidiabetic
[39]
 
2. Antiulcer
[40]
 
3. Insecticidal
[41]
 
4. Antiproteolytic
[42]
 
5. Antiparkinsonian
[43]
 
6. Thrombin Inhibitors
[44]
 
7. Antiinflammatory
[45]
 
8. Analgesic
[46]
 
9. Antifungal
[47]
 
10. Antimicrobial
[48,49]
 
11. CNS effect
[50]
 
12. Antihypertensive
[51]
 
13. Anticonvulsant
[52]
 
14. H1-Histamine antagonists
[53]
 
Tamura et al.
[54] 
have reported antimicrobial activity of 4-thiazolidinone 
derivatives. B. Lohary et al.
[55] 
have synthesised and reported hypolipidemic activity of 
4-thiazolidinone derivatives. Bhawana et al.
[56] 
have assessed some new 4-
thiazolidinones as antiinflammatory agents. Antifungal and antibacterial activity of 
thiazolidinones has been reported
[57]
. O. A. Fathalla
[58]
 have synthesised some new 4-
thiazolidinones as anticancer and antibacterial agent. Mohie A. and co-workers
[59]
 
investigated some new 4-thiazolidinones as anticancer agent. Antiinflammatory and 
analgesic activity of 4-thiazolidinones has been investigated
[60]
. 
Siddique and co-workers
[61]
 have synthesised novel thiazolidinones and evaluated 
for the antithyroid activity. Mayer et al
[62]
.
 
have prepared thiazolidinones and studied 
their herbicidal activity. Archana and  Srivastava
[63]
 have synthesised new 4-
thiazolidinones (II) as potent anticonvulsant agent. S. K. Srivastava et al
[64]
. have 
formulated some new 4-thiazolidinones (I) as antibacterial, antifungal, analgesic and 
diuretic agents. 
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N
N
CH3
O
NH N
S
N
N
S
Ar
O
N
N
N
O
H
N
N
S
Ar
H
O
Ar
H
(I) (II)
 
 
Thiazolidinones useful in the treatment of inflammation have been 
synthesised
[65]
, Govindarajan R. et al
[66]
. have described thiazolidinone derivatives of 
pyrazinoic acid and reported their antibacterial, antifungal and antitubercular activity. 
Thiazolidinones for the inhibition of phosphatases and the treatment of cancer have been 
reported
[67]
. 
Parikh et al. have synthesised variety of 4-thiazolidinones bearing diphenyl 
sulphone
[68]
, substituted aryl
[69,70]
, arsanilic acid
[71]
, 2-aryl-1,3,4-thiadiazole
[72]
, γ-
picolinylamino
[73]
, s-triazine
[74]
, benzoylamino acetamido
[75]
, sulphonamido 
benzoylamino
[76]
, phthalazine-1-yl-amino
[77]
, aryl substituted hydroxyaryl, β-β-
dichloroethylaminophenyl and 8-hydroxyquinolinyl moieties of 4-thiazolidinone ring 
system have been reported as potent antimicrobial agents. 
Moreover, H. H. Parekh and co-workers
[78]
 have synthesized new bis-4-
thiazolidinones and studied their biological activity. A. R. Parikh and coworkers
[79]
 have 
assessed thiazolidinone derivatives bearing 7-methoxyquinoline nucleus for 
antimicrobial activity. 
Dandia et al
[80]
. have synthesized thiazolidinone derivatives and reported their 
antifungal activity. Bioactive venlafaxine analogs such as 2,3-disubstituted-1,3-
thiazolidinones have been synthesized and reported as antimicrobial agent by Kavitha et 
al.
[81]
. Denis et al.
[82]
 have synthesized 4-thiazolidinones derivatives by the cyclization 
unsymmetrical thioureas. Some nickel (II) complexes of 4-thiazolidinone has been 
synthesized by Dave et al.
[83]
 Various worker have applied the Green chemistry approach 
to the synthesis of 4-thiazolidinone derivatives by using microwave assisted method and 
multi component reaction method
[84,85]
. 
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Angela Rao et.al.
[86]
 have been synthesized some novel thiazolidinone 
derivatives(III, IV) and report anti HIV activity. 
N
N
S
R5
R2R1
R4,R3
Y
X
R1
R5 N
S
O
R4
R3
R2
(III) (IV)
 
 
K. H. Patel et. al.
[87]
 have synthesized  2-amino-6-(2-naphthalenyl) thiazolo [3,2-
d]thiadiazole (V)  by treatment of KCNS and Br2 on 2-Amino-4-(2-
naphthalenyl)thiazole. The prepared compounds have been screened on some stains of 
fungai. 
 
S
N
N
S
O
Ar
(V)
 
 
Tejaskumar J. Shah et. al.
[88]
 have been described A series of 2-(substituted 
phenyl)-3-[4-(2,4-dichloro-5-fluorophenyl)-6-(2-thienyl)pyrimidine-2-yl-ureido]-5H/ 
methyl/carboxymethyl-4-thiazolidinones(VI) and screened against different strains of 
bacteria and fungi. 
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F S
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Considerable evidence has been accumulated to demonstrate the wide 
applications of thiazolidinone derivatives and also Pyrazolo[3,4-b]pyridine nucleus have 
drawn the attention of chemists due to diversified biological activities associated with it. 
In view of these findings, it appeared of interest to synthesize, newer thiazolidinone 
derivatives with better potency. 
 
 
 
SECTION-I 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-((Z)PHENYL)-3-(1H-
PRAZOLO[3,4-b]PYRIDINE-3-YL)THIAZOLIDIN -4-ONE 
 
With a view to getting better therapeutic agents and considering the association 
of various biological activities the preparation of thiazolidinone of type (IV) have been 
undertaken by the condensation of N-((Z)benzylidine)-1H-pyrazolo[3,4-b]Pyridine-3-
amine with mercaptoacetic acid in toluene. 
 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 
1
H-nuclear magnetic resonance spectroscopy and further 
supported by mass spectroscopy.  
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REACTION SCHEME 
 
N
N
N
H
N
R
+
HS
OH
O
N
N
NH
N
S
O
R
Dean-Stark
Toluene
Reflux, 10-12 Hrs.
Mercaptoacetic acid
Type (II)
Type (IV)
R = OH, Cl, NO2, N(CH3)2, OCH3 etc.
 
 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
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IR SPECTRAL STUDIES OF 2-(2-CHLOROPHENYL)-3-(1H-PRAZOLO[3,4-
b]PYRIDINE-3-YL)THIAZOLIDIN-4-ONE 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm
-1
 (KBr disc.) 
Type 
Vibration 
Mode 
Frequency cm
-1
 
Ref. 
Observed Reported 
Alkane 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
2953 
2870 
1525 
1329 
2975-2920 
2880-2860 
1470-1435 
1395-1370 
89 
” 
” 
” 
 
Aromatic 
 
C-H str. 
C=C 
C-H i.p. def. 
C-H o.o.p. def. 
3014 
1525 
1122 
889 
3100-3000 
1585-1480 
1125-1090 
860-810 
” 
” 
” 
” 
 
Thiazolidinone 
 
C=O str. 
S-C=N str. 
C–N str. 
C-S str. 
1735 
1631 
1211 
680 
1760-1655 
1640-1605 
1220-1020 
700-600 
90 
” 
” 
” 
Amine 
N-H str. 
N-H def. 
3414 
1631 
3400-3380 
1650-1580 
” 
” 
N
N
H
N
N
CH
S
O
Cl
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1
HNMR SPECTRAL STUDIES OF 2-(2-CHLOROPHENYL)-3-(1H-PRAZOLO 
[3,4-b]PYRIDINE-3-YL)THIAZOLIDIN-4-ONE 
 
 
 
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer  
(300 MHz) 
 
 
Signal 
No. 
Signal Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
3.23-3.92 
6.41 
7.12-7.15 
7.25-7.28 
7.45-7.48 
8.03-8.07 
2H 
1H 
1H 
4H 
1H 
1H 
multiplet 
singlet 
triplet 
multiplet 
multiplet 
multiplet 
-CH (h) 
-CH (i) 
Ar-CH (b) 
Ar-CH (d,e,f,g) 
Ar-CH (c) 
Ar-CH (a) 
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EXPANDED REGION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-((Z)PHENYL)-3-(1H-
PRAZOLO [3,4-b]PYRIDINE-3-YL)THIAZOLIDIN-4-ONE 
 
[A] SYNTHESIS OF N-(2-CHLOROBENZYLIDINE)-1H-PYRAZOLO[3,4-
b]PYRIDINE-3-AMINE 
 
 See Part-II, Experimental Section-I [B]. 
 
[B] SYNTHESIS OF 2-(2-CHLOROPHENYL)-3-(1H-PRAZOLO[3,4-b] 
PYRIDINE-3-YL)THIAZOLIDIN-4-ONE 
 
The Thiazolidinone derivatives have been synthesized by the reaction of N-(2-
Chlorobenzylidene)-3H-Pyrazolo[3,4-b]pyridine-3-amine (0.01 mol, 2.56 gm) in 
Toluene (50.0 ml) and mercaptoacetic acid (0.02 mol, 1.84 gm) was added drop wise at 
room temperature in 15 min and stir for 30 min at room temperature then increase 
temperature slowly up to refluxed and maintain for 10 -12.0 hrs. Remove water by 
azeotropic distillation using a Dean-Stark separator. After completion of reaction, excess 
of toluene was distilled off and the resulting product was treated with 5% NaHCO3 
solution to remove unreacted mercaptoacetic acid. The separated product was washed 
with water, dried and recrystallized from CHCl3 : Water. Yield 68%, m.p. 132
0
C. 
 Similarly other 2-((Z)phenyl)-3-(1H-prazolo[3,4-b]pyridine-3-yl)thiazolidin-4-one 
were prepared. Various physical constants for all the synthesized compounds are given in 
Table 5. 
 
[C] BIOLOGICAL EVALUATION OF 2-((Z)PHENYL)-3-(1H-PRAZOLO [3,4-
b]PYRIDINE-3-YL)THIAZOLIDIN-4-ONE 
 
Antimicrobial testing was carried out as described in Part-II, Experimental Section-
I [C].The results of test solutions are recorded in Table 6. 
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TABLE 6:  BIOLOGICAL EVALUATION OF 2-((Z)PHENYL)-3-(1H-PRAZOLO 
[3,4-b]PYRIDINE-3-YL)THIAZOLIDIN-4-ONE 
 
Sr. 
No. 
Code  
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml 
Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1 3a   500 200 1000 250 >1000 500 1000 
2 3b 500 250 200 500 >1000 500 500 
3 3c 200 1000 200 1000 500 500 200 
4 3d 1000 1000 500 250 1000 250 500 
5 3e 100 500 250 500 1000 500 200 
6 3f 250 100 250 250 250 1000 250 
7 3g 500 200 100 200 500 >1000 1000 
8 3h 62.5 100 1000 250 >1000 500 500 
9 3i 100 100 500 250 >1000 250 500 
10 3j 1000 1000 62.5 100 250 >1000 >1000 
11 3k 500 500 500 250 500 500 1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
E.coli P.aeruginosa S.aureus S.pyogenus 
(microgramme/ml) 
Gentamycin 0.05 1 0.25 0.5 
Ampicillin 100 100 250 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 25 25 50 50 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
 Nystatin 100 100 100 
Greseofulvin 500 100 100 
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ANTIBACTERIAL ACTIVITY:  
From screening results, substituted 4-Thiazolidinone 3h (R = H) against S.aureus  
and 3j (R = -2-Cl) against E-coli possesses very good activity compared with ampicillin 
while 3e (R = -4-OH-3-OCH3) and 3i (R= -4-OCH3) against S.aureus, 3f (R= -4-Cl), 3h 
(R = H) and 3i (R= -4-OCH3) against S.pyogenus possesses moderate activity while 3g 
(R= -4-NO2) and 3j (R = -2-Cl) possesses moderate activity against E-coli and 
P.aeruginosa respectively as  compared with ampicillin. The remaining 4-Thiazolidinone 
derivatives possess poor activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY: 
Antifungal screening data showed that substituted 4-Thazolidinone 3f (R = -4-Cl) 
and 3j (R = -2-Cl) show highly promising activity against C. albicans as compare to 
Greseofulvin while 3d (R = -4-N,N(CH3)2) & 3i (R = -4-OCH3) against A.niger and also  
3f (R = -4-Cl) against A.clavatus show good activity compare with standard drug. The 
remaining compounds exhibited only moderate to poor activity. 
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INTRODUCTION 
 
Heterocycles are abundant in nature and are of great significance to life because 
their structural subunits exist in many natural products such as vitamins, hormones, 
antibiotics etc[1]. Hence, they have attracted considerable attention in the design of 
biologically active molecules[2]. A practical method for the synthesis of such compounds 
is of great interest in synthetic organic chemistry.  
The chemistry of chalcones generated intensive scientific studies throughout the 
world, specially interesting for their biological and industrial applications. Chalcones are 
coloured compounds because of the presence of the chromophore and auxochromes. 
They are known as benzalacetophenones or benzylidene acetophenones. Kostanecki and 
Tambor gave the name Chalcone. The alternative names given to chalcones are phenyl 
styryl ketones, b-phenyl acrylphenone, g-oxo-a,g-diphenyl-apropylene and a-phenyl-b-
benzoethylene. 
The chalcones are α, β-unsaturated ketones containing the reactive ketoethylenic 
group – CO – CH= CH –. Presence of α, β-unsaturated carbonyl system in chalcone 
makes it biologically active. Some substituted chalcones and their derivatives have been 
reported to possess some interesting biological properties such as antibacterial, 
antifungal[3], insecticidal[4], anaesthetic[5], analgesic, ulcerogenic[6] etc. Chalcones, 
considered as the precursor of flavonoids and isoflavonoids, are abundant in edible plants 
[7], and have also been shown to display a diverse array of pharmacological activities, 
such as anti-protozoal [8], anti-inflammatory [9], anticancer [10] and antihyperglycemic 
properties [11]. Consequently, the chalcone backbone could be a versatile scaffold for 
drug design. A survey of the literature revealed that some natural [12,13] and synthetic 
chalcones [14] showed significant ALR2 inhibitory activities, and this prompted us to 
investigate potential ARIs derived from chalcone-based compounds. Thus, we focused 
on the compounds having a carboxylic acid moiety that was incorporated into the 
chalcone backbone and synthesized these compounds. 
 
SYNTHETIC ASPECT 
A considerable variety of methods are available in literature for the synthesis of 
chalcones. The most convenient method is the one, that involves the Claisen-Schimidt 
condensation of equimolar quantities of an aryl methyl ketones with arylaldehyde in 
presence of alcoholic alkali[15]. 
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Chalcones possess conjugated double bonds and a completely delocalized Π-
electron system on both benzene rings. Molecules possessing such system have relatively 
low redox potentials and have a greater probability of undergoing electron transfer 
reactions.  Chalcones are synthesized by claisen-schmidt condensation of aldehyde and 
ketone by base catalyzed or acid catalyzed followed by dehydration to yield chalcones. 
 
MECHANISM 
The following mechanism has been suggested for the synthesis of chalcones. 
 
CH3
O
Ar
OH-
CH2-
O
Ar
H2O
Ar'
O
H CH2-
O
Ar Ar'
O-
H
O
Ar
H2OH+
Ar'
OH
H
O
ArAr'
H
O
ArH2O
(i)
(ii)
+
+
+
 
 
REACTIVITY OF CHALCONES 
The chalcones have been found to be useful for the syntheses of variety of 
Heterocyclic compounds are as under. 
(1) Pyrazolines[16] and their derivatives can be prepared by the condensation of 
chalcones with hydrazine hydrate. 
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(2) Chalcones on reaction with semicarbazide hydrochloride in ethanol affords 1-
carboxamide pyrazolines[17]. 
(3) Chalcones on condensation with malononitrile and ammonium acetate yields 2-
amino-3-cyanopyridines[18]. 
(4) Chalcones on reaction with thiourea in presence of alkali/acid yields 2-
thiopyrimidines[19]. 
(5) Chalcones on treatment with guanidine hydrochloride in presence of alkali 
affords 2-aminopyrimidines[20]. 
(6) Cyanopyridone[21] derivatives can be prepared by the condensation of chalcone 
with ethyl cyanoacetate. 
(7) Chalcones on reaction with 2-aminopyridine in glacial acetic acid affords 
pyridopyrimidines[22]. 
(8) Isoxazoles[23] can be prepared by the reaction of chalcones with hydroxylamine 
hydrochloride and sodium acetate. 
(9) Chalcones on treatment with urea in presence of alkali affords 2-oxo 
pyrimidines[24]. 
(10)  Chalcones react with monoethanolamine in ethanol gives 1,4-oxazipines[25]. 
(11) Oxirane[26] can be prepared by the reaction of chalcone with H2O2 in basic media. 
(12) Chalcones on reaction with barbituric acid gave barbitone[27] derivatives. 
(13) Chalcone gives imine derivatives with amine in presence of sulfuric acid as 
catalyst[28]. 
(14) Chalcones on condensation with malononitrile in pyridine forms 2-amino-3-
cyanopyrans[29]. 
(15) Chalcones react with P2S5 yielded 2-isothiazolidines[30]. 
(16) Chalcones react with sodium nitrile in presence of glacial acetic acid in ethanol 
produces 2-1H-pyrimidines[31]. 
(17) Chalcones with 2-amino thiophenol in acetic acid produces 1,5-thiazepines[32]. 
 
THERAPEUTIC IMPORTANCE 
Chalcone derivatives have been found to possess wide range of therapeutic 
activities as shown below. 
1. Antiallergic[33]
2. Antiinflammatory[34,35] 
3. Antiviral[36]
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4. Anti HIV[37]
5. Carboxygenase inhibitor[38]
6. Antitumor[39,40]
7. Antimalarial[41]
8. Anticancer[42]
9. Antileishmanial[43]
10. Insecticidal[44,45]
11. Antiulcer[46]
12. Bactericidal[47,48]
13. Fungicidal[49-50]
13. Anthelmintics[51]
 Mudalir and Joshi[52]reported insecticidal activity of some phenoxy chalcones. Ko 
et al[53]. have prepared some new chalcones for potent inhibition of platelet aggregation. 
Ziegler et al[54]. reported some chalcones as antiparasitic. The antimalarial activities of 
chalcones have also been reported by Xue et al[55]. and Dominguez et al[56]. Seo et al[57]. 
have synthesized chalcones derivatives and reported them as a-glucosidase inhibitors. 
Larsen and co-worker[58] and Wu et al[59]. have reported anti-plasmodial activity and 
Boeck and et al[60]. have reported anti leishmanial activity of some chalcones. Analogs 
containing nitro, fluorine or bromine group respectively displayed increased selectivity 
against the parasites as compared with natural chalcone. 
Shao-Jie Wang et al.[61] have synthesized chalcones derivatives (I) and reported 
them as a Aldose Reductase Inhibitors. 
 
R1
O
COOH
R2
R3
R1=CH3, OCH3       R3=H,CH3,OCH3,F,Cl
                      R2=H,OH,CH3
(I)
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Recently Ni Liming et al.[62] have synthesized chalcones and screened for their 
antiinflammatory and cardiovascular activity. Kumar Srinivas et al.[63]have synthesized 
chalcones as a antitumor agent. Ko Horng-Huey et al.[64] have prepared chalcones as 
antiinflammatory agent. Nakahara Kazuhiko et al.[65] have synthesized chalcones and 
tested as carcinogen inhibitors. Antitubercular agents of chalcone derivatives have been 
prepared by Lin Yuh-Meei et al.[66]
A. Nagaraj and C. Sanjeeva Reddy[67] reported Antimicrobial, Antifungal 
Activity of some bis-chalcones (II).  
 
R R
O
HO OH
O
R = H, 4-OCH3, 4-Cl, 2-Cl,4-NO2, 4-Br
(II)
 
 
Furthermore, Alcaraz M. J. et al.[68] have described the role of nuclear factor-
kappa B and heme oxygenase-1 in the action of an anti-inflammatory Chalcone 
derivative in RAW 264.7 cells. Nerya O. et al.[69] have prepared some new chalcones as 
potent tyrosinase inhibitors (III).  
 
O
OMe
OMe
OH
O
(III)
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Dong Hwan Shon et al.[70] have synthesized and investigated the anti-
inflammatory activity of 2,4,6-tris(methoxymethoxy)chalcone derivatives. Liu Mei et 
al.[71] have prepared chalcones and screened for antimalarial activity. Opletalova 
Veronika et al.[72] have synthesized chalcones and tested as cardiovascular agents. 
Moreover, it has been found that chalcone derivatives possesses nitric oxide 
inhibitor[73,74] anti HIV[75,76]and antiproliferative[77,78]activities. 
Moreover, Khatib S. et al.[79] synthesized some novel chalcones as potent 
tyrosinase inhibitors (IV). Ko H. H. et al.[80] have prepared some new chalcones for 
potent inhibition of platelet aggregation. Ziegler H. L. et al.[81] reported chalcones as an 
antiparasitic. Go M. L. et al.[82] have described the synthesis and biological activities of 
chalcones as antiplasmodial. A new class of sulfonamide chalcones (V) synthesized and 
their glycosidase inhibitory activity[83] were investigated. 
 
OH
HO
O
OH
OH
(IV)
 
 
O
S
O
O
H
NCH3 R
(V)R = 3 OR 3,4-OH
 
 
N. Lall and co-workers[84] have synthesized 2’,4’,6’-trihydroxy-3’- 
phenylchalcone and 4’,6’,5”-trihydroxy-6”,6”-dimethyldihydropyrano[2”,3”-2’,3’] 
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chalcone as an antiviral and antitubercular agents. M. L. Ferrnandiz et al.[85] have 
synthesized phenylsulphonylurenyl chalcone derivatives with various patterns of 
substitution and tested for their effect on nitric oxide (NO) and prostaglandin 
E2(PGE2)overproduction in RAW 264.7 macrophages. Several derivatives selectively 
inhibited cyclo-oxygenase-2 (COX-2) activity in human monocytes. C. C. Lin et 
al.[86]have examined 1,3-diphenyl-2-propenone for its effect on proliferation in human 
breast cancer cell lines, MCF-7 and MDA-MB-321. 
Shah Alam Khan et al.[87] have synthesized some new chalcones containing 1, 4 - 
dioxane ring system (VI) and reported antihepatotoxic activity. 
R2
R3
R1
O
O
O
X
(VI)
 
 
Das B. P. et al.[88] have found that chalcones possesses larvicidal properties. Kim 
Min-Young et al.[89] have synthesized chalcones and tested for their matrix 
metalloproteinase inhibitor activity. Satyanarayana M. et al.[90] have synthesized 
chalcone derivatives as antihyperglycemic activity (VII). 
O
O
OH
N
H3C
CH3
R
(VII)
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Prem P. Yadav and co-workers[91] have synthesized nitrogen and sulfur 
containing furanoflavonoids and thiophenylflavonoids (VIII), which have been screened 
for antifungal and antibacterial activity. Meng C. Q. et al.[92] discovered some novel 
hetero aryl substituted chalcones as inhibitors of TNF-alpha-induced VCAM-1 
expression (IX). 
X OH
O
R
X = NCH3/S
R = H/OCH3
(VIII)
 
 
H3CO
H3CO
OCH3
O OCH3
OCH3
S
(IX)
 
 
Simon F. Nielsen et. al.[93]have been describes how the introduction of “cationic” 
aliphatic amino groups in the Chalcone scaffold results in potent antibacterial 
compounds        morever Leroy Krbechek et. al.[94]  describes three new, sweet 
dihydrochalcones and related compounds (XI, XII), One of these, 2’,4’,6‘,3 - 
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tetrahydroxy - 4 - n - propoxydihydro-chalcone 4‘-/3-neohesperidoside, was found to be 
preapproximately 2000 times sweeter than sucrose on a weight basis. 
HO
O O
OH
(X)
 
 
 
OHRO
OH
C
O
CH2
H2C
X
Y
OHRO
OH
C
O
CH
HC
X
Y
(XI) (XII)
 
 
Chalcones have been proved to be an important intermediate for the synthesis of 
many heterocyclic compounds in organic chemistry. These facts prompted us to 
synthesize some new chalcone derivatives in order to achieving better therapeutic agents 
described as under.  
With the biodynamic activities of chalcones and it is a good synthon for various 
heterocyclic rings, the interest has been focused on the synthesis of new chalcones. With 
a view to obtained compounds having better therapeutic activity, we have synthesized 
methyl 4-((E)-3-((Z)phenyl)acryloyl)-2-methylbenzoate with various aromatic aldehydes 
in presence of catalytic amount of alkali. 
 
  Chalcones… 
Studies on Some Heterocyclic Entities...... 
 
94
SECTION I 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL 4-((E)-3-
((Z)PHENYL)ACRYLOYL)-2-METHYLBENZOATE 
With the biodynamic activities of chalcones and it is a good synthon for various 
heterocyclic rings, the interest has been focused on the synthesis of new chalcones. With 
a view to obtained compounds having better therapeutic activity, we have synthesized 
Methyl 4-((E)-3-(4-flourophenyl)acryloyl)-2-methylbenzoate by the condensation of 
methyl 4-acetyl-3-methylbenzoate with various aromatic aldehydes in presence of 40% 
alkali. 
The constitution of the synthesized products have been characterized by using 
infrared and 1H-nuclear magnetic resonance spectroscopy and further supported by mass 
spectroscopy.  
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
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REACTIOM SCHEME 
 
O
O
O
CH3
CH3
CH3
HO
O
CH3
O
O
O
CH3
O
CH3
CH3
H
O
R
Reflux
40% NaOH
(Type V)
CH3OH
Con. H2SO4
R = H, OH, OCH3, Cl, NO2, N(CH3)2 etc.
R
Methanol
Methanol
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IR SPECTRAL STUDIES OF METHYL 4-((E)-3-(4-FLOUROPHENYL) 
ACRYLOYL)-2-METHYLBENZOATE 
 
O
O
O
CH3
CH3
F
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc.) 
 
 
Frequency cm-1
Type 
Vibration 
Mode Observed Reported 
Ref. 
Alkane 
(Methane) 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
2987 
2960 
1440  
1285 
2975-2920 
2880-2860 
1470-1435 
1395-1370 
95 
” 
” 
” 
 
Aromatic 
 
C-H str. 
C=C 
C-H i.p. def. 
C-H o.o.p. def. 
3194 
1587 
1093 
831 
3100-3000 
1585-1480 
1125-1090 
860-810 
” 
” 
” 
” 
Ketone C=O str. 1704 1700-1640 ” 
Vinyl CH=CH str. 2987 3050-3000 ” 
Ether 
Halide 
C-O-C str. 
C-F str. 
1259 
1226 
1260-1200 
1400-1100 
” 
96 
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1H NMR SPECTRAL STUDIES OF METHYL 4-((E)-3-(4-FLOUROPHENYL) 
ACRYLOYL)-2-METHYLBENZOATE  
 
Internal Standard: TMS; Solvent: DMSO Instrument: BRUKER Spectrometer 
(400 MHz) 
 
 
Signal 
No. 
Signal Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
2.60 
3.86 
7.29-7.33 
7.89-8.02 
7.75-7.79 
8.04-8.08 
3H 
3H 
2H 
5H 
1H 
1H 
singlet 
singlet 
triplet 
multiplate 
doublet 
doublet 
-CH3(i) 
-CH3(j) 
Ar-CH(d,d’) 
Ar-(c,c’,f,g,h) 
-CH(a) (J=15.6Hz) 
-CH(b)(J=18.8Hz) 
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EXPANDED REGION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL 4-((E)-3-
((Z)PHENYL) ACRYLOYL)-2-METHYLBENZOATE 
 
[A] SYNTHESIS OF METHYL 4-ACETYL-2-METHYLBENZOATE 
 
To a solution of 4-acetyl-2-methylbenzoic acid (0.01 mol, 1.78 gm), Con. 
Sulphuric acid (0.01 mol, 0.53 ml) in methanol (20 ml) was reflux for 5.0 hrs. After 
completion of the reaction excess methanol was distilled off light yellow color oil 
obtained. Yield 98%.  
 
[B] SYNTHESIS OF METHYL 4-((E)-3-(4-FLOUROPHENYL)ACRYLOYL)-
2-METHYLBENZOATE 
To a solution of methyl 4-acetyl-2-methylbenzoate (0.01 mol, 2.22 gm), p-
flourobenzaldehyde (0.01 mol, 1.24 gm) in methanol (25 ml) and 40% NaOH solution 
was added till the solution become basic. The reaction mixture was stirred for 3.0 hrs. at 
room temperature after completion of reaction the content was poured in to crushed ice. 
Upon neutralization the solid separated was crystallized from ethanol. Yield 95%; m.p. 
2350C.  
Similarly other methyl 4-((E)-3-((Z)phenyl)acryloyl)-2-methylbenzoate were 
obtained. Various physical constants for all the synthesized compounds are given in 
Table 7. 
 
[C] BIOLOGICAL EVALUATION OF METHYL 4-((E)-3-((Z)PHENYL) 
ACRYLOYL)-2-METHYLBENZOATE 
Antimicrobial testing was carried out as described in Part-II, Experimental Section-
I [C]. The results of of test solutions are recorded in Table 8. 
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TABLE 8: BIOLOGICAL EVALUATION OF METHYL 4-((E)-3-((Z)PHENYL) 
ACRYLOYL)-2-METHYLBENZOATE  
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml 
Gram +ve Bacteria Gram –ve Bacteria 
Minimal fungicidal concentration 
μg/ml Sr. 
No. Code  
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1 4a  500 100 50 1000 500 1000 500 
2 4b 1000 500 1000 250 250 >1000 >1000 
3 4c 100 1000 500 100 500 250 1000 
4 4d 500 1000 1000 500 1000 250 500 
5 4e 1000 250 200 1000 500 500 250 
6 4f 62.5 500 500 200 500 500 500 
7 4g 1000 100 200 1000 1000 1000 500 
8 4h 50 1000 500 200 200 >1000 >1000 
9 4i 200 1000 1000 1000 >1000 1000 250 
10 4j 1000 500 250 250 500 500 1000 
11 4k 250 250 250 250 500 1000 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
E.coli P.aeruginosa S.aureus S.pyogenus 
Standard Drugs 
(microgramme/ml) 
Gentamycin 0.05 1 0.25 0.5 
Ampicillin 100 100 250 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 25 25 50 50 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
C.Albicans A.Niger A.Clavatus 
Standard Drugs 
(microgramme/ml) 
 Nystatin 100 100 100 
Greseofulvin 500 100 100 
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ANTIBACTERIAL ACTIVITY:  
From screening results, substituted chalcones 4f (R = -4-Cl) and 4h (R = H) 
against S.aureus  and 4a (R = -2-OH) against E-coli possesses very good activity 
compared with ampicillin while 4c (R = -4-OH) against S.aureus, 4a (R= -2-OH) and 4g 
(R= -4-NO2) against S.pyogenus and 4c (R = -4-OH) against P.aeruginosa possesses 
moderate activity as  compared with ampicillin. The remaining 4-Thiazolidinone 
derivatives possess poor to very poor activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY: 
Antifungal screening data showed that substituted chalcones 4b (R = -3-NO2) and 
4h (R = H) show highly promising activity against C. albicans as compare to standard 
drug Greseofulvin while 4c (R = -4-OH) and 4d (R = -4-N,N(CH3)2) against A.niger and 
also  4e (R = -4-OH-3-OCH3) and 4i (R = -4-OCH3) against A.clavatus show good 
activity compare with standard drug. The remaining compounds exhibited only moderate 
to poor activity. 
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INTRODUCTION 
 
Amongst nitrogen containing five membered heterocycles, pyrazolines have 
proved to be the most useful framework for biological activities. Pyrazolines have 
attracted attention of medicinal chemists for both with regard to heterocyclic chemistry 
and the pharmacological activities associated with them. The pharmaceutical importance 
of these compounds lies in the fact that they can be effectively utilized as antibacterial, 
antifungal, antiviral, antiparasitic, antitubercular and insecticidal agents. In 1967 Jarboe, 
reviewed the chemistry of pyrazolines, which have been studied extensively for their 
biodynamic behavior and industrial applications. 
 
N
N
H
 
 
As evident from the literature, in recent years a significant portion of research 
work in heterocyclic chemistry has been devoted to pyrazolines containing different aryl 
groups as substituents. 
 
SYNTHETIC ASPECTS 
Different methods for the preparation of 2-pyrazoline derivatives documented in 
literature are as follows. 
1. The most common procedure for the synthesis of 2-pyrazolines is the reaction of 
an aliphatic or aromatic hydrazine with α,β-unsaturated carbonyl compounds. 
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N NH2 N
N
R2
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+
 
2. 2-Pyrazolines synthesized by the cycloaddition of diazomethane with substituted 
chalcones
[1]
.  
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3. 2-Pyrazolines can also be prepared by the condensation of chalcone 
dibromidewith hydrazine
[2]
. 
4. Epoxidation of chalcones i.e. epoxy ketones which reacted with hydrazine and 
phenyl hydrazine to give pyrazolines
[3]
. 
5. A number of diarylidene cycloalkanones on reaction with hydrazine hydrate 
produce pyrazolines
[4]
. 
6. Dipolar cyclo addition of nitrilimines to dimethyl fumarate, fumaro nitrile and 
the N-aryl maleimides yields the corresponding pyrazolines
[5]
. 
7. Reaction of Et 2-(phenylazo)-3-oxobutanoates with nicotinic acid hydrazide 
using glacial acetic acid gives following type of pyrazoline derivatives
[6]
. 
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H
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N
N
CH3
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Several methods are employed in the synthesis of pyrazolines, including the 
condensation of chalcones with hydrazine hydrate
[7-11]
. 
 
MACHANISIM 
 
The following mechanism seems to be operable for the condensation of 
chalcones 
With hydrazine hydrate
[12]
. 
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Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl 
system (I) forms species (II), in which the negative charge is mainly accommodated by 
the electronegative oxygen atom. Proton transfer from the nitrogen to negative oxygen 
produces an intermediate enol which simultaneously ketonises to ketoamine (III). 
Another intramolecular nucleophilicattack by the primary amino group of ketoamine on 
its carbonyl carbon followed by proton transfer from nitrogen to oxygen leads ultimately 
to carbonyl amine (IV). The later with a hydroxy group and amino group on the same 
carbon lose water molecule to yield the pyrazolines (V). 
 
THERAPEUTIC IMPORTANCE 
Pyrazole belongs to the family of azoles i.e. five-membered ring containing 
nitrogen and carbon atom. Considerable attention has been focused on pyrazolines and 
substituted pyrazolines due to their interesting biological activities. The dihydro 
pyrazoles are called pyrazolines. Some substituted pyrazolines and their derivatives have 
been reported to possess some interesting biological activities such as anticancer
[13]
, 
insecticidal
[14]
, antibacterial
[15]
 etc. They have found to possess antifungal
[16]
, 
antidepressant
[17-20]
, anticonvulsant
[21,22]
, anti-inflammatory
[23]
, antibacterial
[24]
 and anti-
tumor
[25]
 properties. Moreover, many selectively fluoro-substituted organic compounds 
show peculiar pharmacological and agrochemical properties
[26-29]
.  
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Udupi R. H. and Bhatt A. R.
[30] 
have reported the synthesis and biological 
activity of Mannich bases of certain 1,2-pyrazolines. Nugent Richard
[31]
 investigated 
pyrazolines bis phosphonate ester as novel antiinflammatory and antiarthritic agent. 
Fuche Rainer et al.
[32] 
have prepared some new 1H-pyrazoline derivatives (VI) and 
reported them as pesticides. Furthermore, Tsubai et al.
[33] 
have synthesized some new 
(phenylcarbamoyl) pyrazolines (VII) as an insecticides and at 40% concentration shows 
100% mortality of spodopetra litura larve after seven drops. 
 
N
NH
N
N
Cl
N
N
NH
O
F3C
R
(VI) (VII)
 
 
Several pyrazolines bearing thymol moiety were evaluated for their ability as 
potent antimicrobial by K. P. Roda.
[34] 
Jatin Upadhyay et al.
[35] 
have described the 
pyrazoline derivatives and their use as antimicrobial agents. H. J. Vikani and co-
workers
[36] 
have prepared pyrazoline derivatives from arsanilic acid for their 
antimicrobial activity. Parekh et al.
[37] 
have synthesised and reported the antimicrobial 
activity of pyrazoline derivatives.  
T. Atif and co-workers
[38] 
have patented 3-methyl-4'-(substituted phenylazo)-
pyrazol-5-ones as antibacterial agents. R. H. Udupi and A. R. Bhat
[39] 
have reported the 
synthesis and biological activity of Mannich bases of certain 1,2-pyrazolines. Pyrazoline 
derivatives of salicylic acid possessing antimicrobial properties have been reported
[40]
. 
T. M. Stavenson et al.
[41] 
have investigated N-substituted pyrazoline type 
insecticides. T. Katsuhori
[42] 
have patented pyrazoline derivatives as herbicides. 
Pyrazolines derivatives showing significant antibacterial activity are described
[43]
. 
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Parekh et al.
[44] 
have prepared 1-acetyl-5-aryl-3-[3-(3,4-dihydro-2-methyl-4-one-
3-quinazolinyl)-phenyl]-2-pyrazolines which possess antimicrobial activity. Akhil Bhatt 
and co-workers
[45] 
have reported pyrazoline derivatives showing antimicrobial activity. 
Parekh et al.
[46] 
have synthesised acetyl pyrazolines derivatives bearing quinoline moiety 
(VIII) and described their antimicrobial activity. 
 
N
N
N
R
O
CH3
Cl
(VIII)
 
 
E. Palaska et al.
[47]
 have prepared 3,5-diphenyl-2-pyrazolines (IX) and cited their 
antidepressant activity. B. Shivrama et al.
[48,49]
 have synthesized pyrazolines as 
antibacterial agents. Hiremath S. P. et al.
[50]
 have reported pyrazolines as analgesics, 
antiinflammatory and antimicrobial agents. Goodell et al.
[51]
 have synthesized some 
newer 1,3,5-trisubstituted pyrazoline derivatives which shows anti westnile virus activity 
(X). F. Manna and co-workers
[52]
 have described 1-acetyl-5-(2'-bromophenyl)-4,5-
dihydro-3-(2'-hydroxyphenyl)-1H-pyrazoline and its derivatives which acts as potent 
bioactive agents.  
N
NHR1
R2
MeO
OMe
N
N
S
R2
R1
(IX)
(X)
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Some pyrazoline derivatives have been studied for their antidepressant 
activity
[53]
. Eggenweiler and co-workers
[54]
 have reported some pyrazoline derivatives as 
inhibitors of cGMP and cAMP phosphodiesterase. Pyrazoline derivatives of anthranilic 
acid (VIII) as potent antiinflammatory agents have been investigated
[55]
. Maurer et al.
[56]
 
have prepared pyrazolines and reported their pesticidal activity. K. Mogilaiah and 
Sudhakar
[57]
 have prepared 1,8-naphthyridinyl-2-pyrazolines and studied their 
antibacterial activity. 
 
NH
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N O
CH3
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S. S. Sonarc et al.
[58]
 have synthesized-3-(2-acetoxy-4-methoxyphenyl)-5-
(substituted phenyl)-pyrazolines and tested their antimicrobial activity. H. S. Joshi
[59]
 et 
al. have also synthesized some new pyrazolines as an antimicrobial agent. G. N. 
Mishirika et al.
[60]
 have prepared 2-pyrazolines of salicyclic acid possessing 
antimicrobial properties. Tunfawy Atif and co-workers
[61]
 have patented 3-methyl-4'-
(substituted phenylazo)-pyrazol-5-ones as antibacterial agents. 
 
This, significant biological properties associated with pyrazoline derivatives have 
aroused considerable interest to design the compounds with better drug potentials and to 
study their pharmacological profile, which have been described as under. 
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SECTION I 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF METHYL-4-(4,5-DIHY-
DRO-5-((Z)PHENYL)-1H-PYRAZOL-3-YL)-2-METHYLBENZOHYDRAZIDE 
 
Considerable attention has been focused on the development and synthesis of 
pyrazolines of type (VI) for obtaining biologically potent molecules which have been 
prepared by the condensation of chalcones of type (V) with hydrazine hydrate in 
ethanol. 
 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 
1
H-nuclear magnetic resonance spectroscopy and further 
supported by mass spectroscopy. 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
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REACTION SCHEME 
 
CH3
H3COOC
O
R
NH2-NH2 .H2OEthanol
H2NHNOC
CH3
NH
N
R
Type (V)
Type (VI)
R = H, OH, Cl, NO2, OCH3 etc.
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IR SPECTRAL STUDIES OF 4-(5-(4-FLUOROPHENYL)-4,5-DIHYDRO-1H-
PYRAZOL-3-YL)-2-METHYLBENZOHYDRAZIDE 
 
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm
-1
 (KBr disc.) 
 
Type 
Vibration 
Mode 
Frequency cm
-1
 
Ref. 
Observed Reported 
Alkane 
(Methane) 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
2958 
2858 
1483 
1377 
2975-2920 
2880-2860 
1470-1435 
1395-1370 
62 
” 
” 
” 
 
Aromatic 
 
C-H str. 
C=C 
C-H i.p. def. 
C-H o.o.p. def. 
3097 
1556 
1024 
840 
3100-3000 
1585-1480 
1125-1090 
860-810 
” 
” 
” 
” 
 
Pyrazoline 
 
C=N str. 
C–N str. 
C=O str. 
1512 
1201 
1681 
1580-1520 
1220-1020 
1612-1700 
” 
” 
” 
Amine 
Halide 
N-H str. 
C-F str. 
3387 
1257 
3410-3380 
1400-1100 
’’ 
63 
H2NHNOC
H3C
NH
N
F
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1
H NMR SPECTRAL STUDIES OF 4-(5-(4-FLUOROPHENYL)-4,5-DIHYDRO-
1H-PYRAZOL-3-YL)-2-METHYLBENZOHYDRAZIDE 
 
Internal Standard: TMS; Solvent: DMSO Instrument: BRUKER Spectrometer 
(400 MHz) 
Signal 
No. 
Signal Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
2.09 
2.50 
2.50-2.55 
2.56-2.61 
7.15 
7.29-7.32 
7.45-7.46 
7.75-7.78 
7.82-7.85 
7.86-7.92 
7.94 
13.61 
3H 
1H 
1H 
1H 
1H 
2H 
2H 
1H 
1H 
1H 
1H 
2H 
singlet 
doublet 
doublet 
triplet 
singlet 
triplet 
multiplet 
doublet 
doublet 
multiplet 
singlet 
singlet 
-CH3  
-CH (d) 
-CH (d) (J=20 Hz) 
-CH (e) 
-NH (h) 
Ar-CH (g,g’) 
Ar-CH (f,f’)  
Ar-CH (a) (J=12 Hz) 
Ar-CH (c) (J=12 Hz) 
Ar-CH (b) 
-NH(i) 
-NH2 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(5-((Z)PHENYL)-4,5-
DIHYDRO-1H-PYRAZOL-3-YL)-2-METHYLBENZOHYDRAZIDE 
 
[A] SYNTHESIS OF METHYL 4-((E)-3-(4-FLOUROPHENYL)ACRYLOYL)-
2-METHYLBENZOATE 
 See Part-IV, Experimental Section-[B]. 
 
[B] SYNTHESIS OF 4-(5-(4-FLUOROPHENYL)-4,5-DIHYDRO-1H-
PYRAZOL-3-YL)-2-METHYLBENZOHYDRAZIDE 
 
A mixture of methyl 4-((E)-3-(4-flourophenyl)acryloyl)-2-methylbenzoate (0.01 
mol, 2.98 gm) and hydrazine hydrate (0.05 mol, 1.25 gm) in 25 ml Ethanol was refluxed 
for 10 hrs. The solution was poured into crushed ice and neutralize with dilute HCl 
solution. Product was isolated and crystallized from ethanol. Yield 70%, m.p. 153
0
C.  
 Similarly, other 4-(5-((Z)phenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2-methyl- 
benzohydrazide were prepared. The physical data are recorded in Table 9. 
 
[C] BIOLOGICAL EVALUATION OF 4-(5-((Z)PHENYL)-4,5-DIHYDRO-1H-
PYRAZOL-3-YL)-2-METHYLBENZOHYDRAZIDE 
 
 Antimicrobial testing were carried out as described in Part-II, Experimental 
Section-I [C]. The results of test solutions are recorded in Table 10. 
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TABLE 10: BIOLOGICAL EVALUATION OF 4-(5-((Z)PHENYL)-4,5-
DIHYDRO-1H-PYRAZOL-3-YL)-2-METHYLBENZOHYDRAZIDE 
Sr. 
No. 
Code  
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration 
μg/ml 
Gram +ve Bacteria Gram –ve Bacteria 
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1 5a   250 100 500 50 1000 250 1000 
2 5b 500 500 100 100 500 500 500 
3 5c 100 250 1000 500 500 500 >1000 
4 5d 1000 500 250 500 >1000 1000 200 
5 5e 200 100 250 250 500 500 250 
6 5f 100 250 500 200 1000 250 500 
7 5g 62.5 500 250 500 500 500 500 
8 5h 250 1000 500 1000 200 >1000 1000 
9 5i 250 200 1000 250 200 1000 500 
10 5j 500 1000 1000 1000 500 500 250 
11 5k 250 200 500 500 1000 500 1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
Standard Drugs 
E.coli P.aeruginosa S.aureus S.pyogenus 
(microgramme/ml) 
Gentamycin 0.05 1 0.25 0.5 
Ampicillin 100 100 250 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 25 25 50 50 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
Standard Drugs 
C.Albicans A.Niger A.Clavatus 
(microgramme/ml) 
 Nystatin 100 100 100 
Greseofulvin 500 100 100 
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ANTIBACTERIAL ACTIVITY:  
From screening results, substituted Pyrazolines 5g (R= -4-NO2) against S.aureus  
and 5a (R = -2-OH) against P.aeruginosa possesses very good activity compared with 
ampicillin while 5f (R= -4-Cl) against S.aureus, 5a (R = -2-OH), 5e (R = -4-OH-3-
OCH3) against S.pyogenus while 5b (R= -3-NO2) against E-coli and also against 
P.aeruginosa possesses very good activity as  compared with ampicillin. The remaining 
pyrazoline derivatives possess poor activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY: 
Antifungal screening data showed that substituted pyrazoline 5h (R= H) and 5i 
(R = -4-OCH3) show highly promising activity against C. albicans as compare to 
Greseofulvin while 5a (R = -2-OH) & 5f (R = -4-Cl) against A.niger and also 5e (R = -
4-OH-3-OCH3) and 5j (R = -2-Cl) against A.clavatus show good activity compare with 
standard drug. The remaining compounds exhibited only moderate to poor activity. 
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INTRODUCTION 
Isoxazole is a five membered heterocyclic compound having two hetero atoms: 
oxygen at position 1 and nitrogen at position 2. Claisen first reported an isoxazole (I) for 
a product from the reaction of 1,3 diketone with hydroxylamine hydrochloride[1] 
.Subsequently a solid foundation for the chemistry of isoxazole was laid down by 
Claisen and his students. It was shown to possess typical properties of an aromatic 
system but under certain reaction conditions. Particularly in reducing or basic media, it 
becomes very highly labile. 
N
O
1
2
3 4
5
(I)
 
 
The next important contribution to the chemistry of isoxazoles was made by 
Quelico[2] in 1945, when he begane to study the formation of isoxazoles from nitrile N-
oxide and unsaturated compounds. 
 
 
SYNTHETIC ASPECT 
 
Isoxazoles can be prepared by various methods; some of them are described as 
under. 
1. A variety of 3,5-disubstituted 4-bromoisoxazoles[3]  (II) are readily prepared in 
good to excellent yields under mild reaction conditions. 
 
CH3
O
NH2OMe HCl
CH3
N
O
CH3
Br2
ON
Br
(II)
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2. Tayade V. B. et al.[4] have synthesized some new 3,5-diarylisoxazoles from the 
reaction of 2-aryl acetophenones with hydroxyl amine hydrochloride in presence 
of alkali. 
3.  Dawood Kamal et al.[5] have prepared isoxazole derivatives from enamino 
nitriles. 
4.  Mark Lautens and Ame´lie Roy[6] have constructed isoxazoles (III), 
wereachieved in good yields in a rapid and simple way by using N-acetoacetyl 
derivatives. 
 
N
H3C
O
CH3
H3C
O
CH3
NH2OH.HCl
NaOAc,  MeOH
O
N
H3C
H3C N
H3C
CH3
(III)
 
5. Solid phase synthesis of isoxazole derivatives based on aminoacids was reported 
by Lidia De Luca and co-workers[7] in the presence of basic catalyst and 
dichloromethane used as a solvent. One pot synthesis of polyfunctionalized 
isoxazoles[8] have been synthesized by the reaction of dipyrrolidinium 3,3-
dimethylpentanedinitrile-2,4-dinitronate and acetyl chloride in benzene. 
6. Keisuke Suzuki et al.[9] have synthesized functionalized isoxazole derivatives 
(IV) by cyclocondensation of C-chlorooximes with cyclic 1,3-diketones. 
 
O
H3C
Cl
N
OH
O
O
PrOH
NaO/Pr
O
H3C ON
O
(IV)
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7.  Crawley L. S. and Fan Shawe W. J.[10] have prepared isoxazole (V) from α,β-
unsaturated carbonyl compounds, hydroxyl amine hydrochloride and KOH in 
methanol. 
R R1
O
NH2OH.HCl
KOH
N
O
R
R1
(V)
 
 
8. R. Kalirajan et al.[11] have synthesized and check antimicrobial screening against 
various gram positive and Gram negative bacteria and anti fungal activity against 
various fungal stains compared with standard drug (Ampicillin and 
Ketoconazole) using solvent control. 
 
O
O
N
H3C
(VI)
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REACTION MECHANISM 
R1
R O
HO NH2 HCl
R1
R O-
OH+
NH2
-H+
R1
R O
O
:NH2
-
H+
R1
R
O
NH2
O-
+
R1
R
O
NH
OH
Proton Transfer-H2O
H+
R1
R
O
NH-
-H+
R1
R
O
N
R1
C
R
O
N
-2H+
OH
 
THERAPEUTIC IMPORTANCE 
Isoxazole derivatives exhibit various biological activities such as, 
1.  Antibacterial[12-14]
2.  Anticonvulsant[15,16]
3.  Anticholestermic[17]
4.  Anticancer[18]
5.  Anthelmintics[19]
6.  Antiinflammatory[20-23]
7.  Adenosine antagonist[24]
8.  Fungicidal[25-27]
9.  Herbicidal[28,29]
10.  Hypoglycemic[30]
11.  Muscle relaxant[31,32]
12.  Nematocidal[33]
13.  Insecticidal[34]
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14.  Antiviral[35]
15.  Antimicrobial[36]
Aicher Thomas D. et al.[37] reported isoxazoles (VII) as hypoglycemic agents. H. 
S. Joshi et al.[38] have synthesized isoxazole derivatives (VIII) and reported their 
antitubercular and antimicrobial activity. 
N
O
Cl
Cl
O
ClH2C
Br
O
N
R
(VII) (VIII)
 Julia Kaffy et al.[39] have been synthesized various five membered heterocycles 
with oxygen and nitrogen atoms. The 4,5-diarylisoxazole (IX) exhibited greater 
antitubulin activity, but modest antiproliferative activity. Kai Fan Cheng [40] have been 
synthesized 3-(4-hydroxyphenyl)-4,5-dihydro-5-aceticacidmethylester isoxazole, an 
inhibitor of the proinflammatory cytokine MIF, two critical modifications and chiral 
resolution have significantly improved the potency of the inhibition. Compound (X) 
inhibits MIF tautomerase with an IC50 of 550 nm. 
O
O
O
H3C
CH3
CH3
N
O
OH
O
CH3
(IX)
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HO
F
O
N
O
O
CH3H3C
CH3
(X)
 
 
Welsing P. M. et al.[41] have documented the isoxazoles as tumor necrosis 
factorblocking agents and leflunomide for treating rheumatoid arthritis in the 
Netherlands. Bingham S. J. et al.[42] have synthesized isoxazole derivatives as an 
antiulcer agents. Barbachyn M. R. et al.[43] have described the phenylisoxazolines as 
novel and viable antibacterial agents active against Gram-positive pathogens. Masui et 
al.[44] have prepared isoxazoles having pesticidal activity. Some isoxazoles gave 
excellent herbicidal results obtained by Reddy et al.[45]. 
Stefano Chimichi and co-workers[46] have investigated cytotoxic activity of 3-
quinolinoyl isoxazoles (XI) against leukemia and adenocarcinoma derived cell lines in 
comparison to the normal human keratinocytes. Novel cyclohexyl drug resistance 
modulators[47] (XII) were synthesized and evaluated for in vitro inhibition of the drug 
resistance transporter. 
N
CH3
OH
O
NO
N
O
N
CH3O
HN O
Cl
(XI) (XII)
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Moreover, S. Rung and D. Dus[48] have synthesized some new isoxazoles as 
remedy for leukemia. M. Scobie and co-workers[49] have prepared isoxazole derivatives 
and studied their antitumor activity. G. Daidone et al.[50] synthesized 3-(isoxazol-3-yl)-
quinazolin-4-(3H)-one derivative and tested for their analgesic and antiinflammatory 
activities as well as for their acute toxicity and ulcerogeniceffect. Salter M. W. et al.[51] 
have prepared some isoxazole as cellular neuroplasticity mechanisms mediating pain 
persistence. Matringe M. et al.[52] have reported some new p-hydroxyphenylpyruvate 
dioxygenase inhibitor resistant plants. Mehlisch D. R. et al.[53] have synthesized 
isoxazole derivative as analgesic efficacy of intramuscular parecoxib sodium in 
postoperative dental pain. Ray W. A. et al.[54] have reported isoxazole derivative as 
cardiovascular toxicity of valdecoxib. 
With an intension of preparing the compounds possessing better therapeutic 
activity, we have under taken the preparation of isoxazoles bearing 4-acetyl-2-
methylbenzoic acid nucleus which have been described as follows. 
 
 
 
SECTION I 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(5-((Z)PHENYL)ISOXA 
-ZOL-3-YL)-2-METHYLBENZOIC ACID 
 
Isoxazole derivatives have attracted considerable attention due to their potential 
biodynamic behaviour. In view of these valid observations, the synthesis of some new 
isoxazoles of Type (VII) has been undertaken by the reaction of chalcones of Type (V) 
with hydroxylamine hydrochloride in presence of 40% KOH in 95% ethanol. 
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REACTION SCHEME 
CH3
O
R
NH2OH.HCl40% KOH
95% Ethanol
HOOC
CH3
ON
R
Type (V)
Type (VII)
R = OH, Cl, NO2, OCH3, N(CH3)2 etc.
O
O
CH3
 
 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further 
supported by mass spectroscopy.  
 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
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IR SPECTRAL STUDIES OF 4-(5-(4-FLUOROPHENYL)ISOXAZOL-3-YL)-2-
METHYLBENZOIC ACID 
 
N
HOOC
O
CH3
F
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
 4000-400 cm-1 (KBr disc.) 
 
Frequency cm-1
Type 
Vibration 
Mode Observed Reported 
Ref. 
Alkane 
(Methane) 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
2941 
2847 
1450  
1321 
2975-2920 
2880-2860 
1470-1435 
1395-1370 
55 
” 
” 
” 
 
Aromatic 
 
C-H str. 
C=C 
C-H i.p. def. 
C-H o.o.p. def. 
3066 
1483 
1130 
817 
3100-3000 
1585-1480 
1125-1090 
860-810 
” 
” 
” 
” 
Isoxazole 
C=C str. 
C=N str. 
N-O str. 
1604 
1533 
817 
1680-1550 
1690-1460 
850-810 
56 
” 
” 
Acid 
Halide 
C=O str. 
C-F str. 
1720 
1238 
1710-1650 
1400-1100 
” 
” 
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1H NMR SPECTRAL STUDIES OF 4-(5-(4-FLUOROPHENYL)ISOXAZOL-3-
YL)-2-METHYLBENZOIC ACID 
 
Internal Standard: TMS; Solvent: DMSO Instrument: BRUKER Spectrometer 
(400 MHz) 
 
 
Signal 
No. 
Signal Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
7 
2.55 
5.81 
7.21-7.26 
7.40-7.47 
7.62-7.68 
7.82-7.89 
7.98-8.01 
3H 
1H 
2H 
2H 
1H 
1H 
1H 
singlet 
singlet 
triplet 
multiplet 
triplet 
multiplet 
multiplet 
-CH3  
-CH (d) 
Ar-CH (f,f’) 
Ar-CH (e,e’) 
Ar-CH (a) 
Ar-CH (c) 
Ar-CH (b) 
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EXPANDED REGION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(5-
((Z)PHENYL)ISOXAZOL-3-YL)-2-METHYLBENZOIC ACID 
 
[A] SYNTHESIS OF METHYL 4-((E)-3-(4-FLOUROPHENYL)ACRYLOYL)-
2-METHYLBENZOATE 
 
 See Part-IV, Experimental Section-[B]. 
 
[B] SYNTHESIS OF 4-(5-(4-FLUOROPHENYL)ISOXAZOL-3-YL)-2-   
METHYLBENZOIC ACID 
 
A mixture of methyl 4-((E)-3-(4-flourophenyl)acryloyl)-2-methylbenzoate (0.01 
mol, 2.98 gm) and Hydroxylamine hydrochloride (0.01 mol, 0.695 gm) in ethanol (20 
ml) was refluxed on waterbath in presence of alcoholic KOH for 14 hrs. The excess 
solvent was distilled off and the residue was neutralized with 20% HCl, the separated 
solid was filtered out and crystallized from methanol. Yield 62 %, m.p. 1630C.  
Similarly, other 4-(5-(4-fluorophenyl)isoxazol-3-yl)-2-methylbenzoic acid were 
prepared. The physical data are recorded in Table 11. 
 
[C] BIOLOGICAL EVALUATION OF 4-(5-((Z)PHENYL)ISOXAZOL-3-YL)-
2-METHYLBENZOIC ACID 
 
 Antimicrobial testing were carried out as described in Part-II, Experimental 
Section-I [C]. The results of test solutions are recorded in Table 12. 
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TABLE 12: BIOLOGICAL EVALUATION OF 4-(5-((Z)PHENYL)ISOXAZOL-
3-YL)-2-METHYLBENZOIC ACID 
Antibacterial Activity Antifungal Activity 
Minimal bactericidal concentration μg/ml 
Gram +ve Bacteria Gram –ve Bacteria 
Minimal fungicidal concentration 
μg/ml Sr. 
No. 
Co
de  
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1 6a   500 200 100 1000 500 1000 500 
2 6b 500 1000 500 250 1000 250 500 
3 6c 200 500 500 500 250 200 1000 
4 6d 1000 100 1000 200 500 >1000 500 
5 6e 100 500 200 100 200 500 250 
6 6f 100 200 200 50 >1000 500 1000 
7 6g 1000 500 250 250 >1000 500 500 
8 6h 1000 200 250 1000 500 500 >1000 
9 6i 200 1000 250 200 500 1000 500 
10 6j 100 250 250 500 500 250 500 
11 6k 500 500 500 500 1000 500 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
E.coli P.aeruginosa S.aureus S.pyogenus 
Standard Drugs 
(microgramme/ml) 
Gentamycin 0.05 1 0.25 0.5 
Ampicillin 100 100 250 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 25 25 50 50 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
C.Albicans A.Niger A.Clavatus 
Standard Drugs 
(microgramme/ml) 
 Nystatin 100 100 100 
Greseofulvin 500 100 100 
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ANTIBACTERIAL ACTIVITY:  
From screening results, substituted Isoxazoles  6f (R = -4-Cl) possesses very 
good activity against P.aeruginosa compared with ampicillin while 6e (R = -4-OH-3-
OCH3), 6f (R = -4-Cl) and 6j (R = -2-Cl) against S.aureus, 6d (R = -4-N,N(CH3)2 
against S.pyogenus, 6a (R = -2-OH) against E-coli and 6e (R = -4-OH-3-OCH3) against 
P.aeruginosa possesses moderate activity as compared with ampicillin. The remaining 
Isoxazole derivatives possess poor to very poor activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY: 
 
Antifungal screening data showed that substituted Isoxazoles 6e (R = -4-OH-3-
OCH3) against C.albicans and 6a (R = -2-OH) against A.niger, show highly promising 
activity compare with standard drug. While 6c (R = -4-OH) against C.albicans, 6b (R = -
3-NO2) and 6j (R = -2-Cl) against A.niger while 6e (R = -4-OH-3-OCH3) against 
A.clavatus exhibited moderate activity. The remaining compounds exhibited poor 
activity against all three bacterial species.  
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INTRODUCTION 
 
Heterocycles are abundant in nature and are of great significance to life because 
their structural subunits exist in many natural products such as vitamins, hormones, 
antibiotics etc. Hence, they have attracted considerable attention in the design of 
biologically active molecules. Oxopyrimidines and its derivatives represent one of the 
most active class of compounds possessing a wide spectrum of biological activities. 
Pyrimidine derivatives which occurs in natural products like nucleic acid, vitamin-B and 
having remarkable pharmaceutical importance because of their broad spectrum of 
biological activities. Several analogs of nucleic acids like fluorouracil which has been 
used in cancer treatment. Pyrimidines are among those molecules that make life possible 
as being some of the building blocks of DNA and RNA. 
Pyrimidine is considered to be a resonance hybrid of the charged and uncharged 
cannonical structures, its resonance energy has been found to be less than benzene or 
pyridine. The naturally occuring pyrimidine derivatives was first isolated by Gabrial and 
Colman in 1870, and its structure was confirmed in 1953 as 5-β-D-gluco-pyranoside of 
divicine. 
 
Some oxo pyrimidines of physiologically as well as therapeutically importance 
are as under: e.g., Blasticidin, Zidovudine. 
 
 
N
N
O
O
COOH
H
N
O NH2
CH3
NH2
NH
Blasticidin
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HN
NO
H3C
O
O
CH3
HO
Zidovudine
 
 
 
SYNTHETIC ASPECT 
 
Different methods for the synthesis of pyrimidinones have been cited in the 
literature[1]. 
An efficient and robust solid-phase synthesis of 6-substituted-2,5,6,8-tetrahydro-
3H-imidazo[1,2-a]pyrimidin-7-one (II), 3-substituted-1,3,4,6,7,8-exahydropyrimido[1,2-
a]pyrimidin-2-ones (III) using Baylis Hillman reagent[2]. 
 
HN
NN
O R
HN
NN
R
O
(II) (III)
 
 
Oliver Kappe et al.[3] have synthesized dihydropyrimidine-5-carboxylicacid (IV) 
in two steps by multicomponent condensation of benzyl or allyl β-ketoesters with 
aldehyde and urea, followed by suitable benzyl or allyl deprotection strategies. 
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N
NH
R2
R1
HO
O
O
R3
(IV)
 
 
The condensation of the azaenolates derived from readily available ketimines 
with fluorinated nitriles offers an efficient and straightforward entry to new fluorinated 
1,3-vinylogous amides. These versatile compounds in turn react with triphosgene to 
yield new fluorinated pyrimidin-2(1H)-ones (V) in high yields[4]. 
 
R1 N
R2
CH3
N RF R1 N
R2
CH
H2N
RF N N
O
R1
R2 RF
CO
(V)
 
 
Fikret karci et al.[5] have synthesized 4-amino-1H-benzo[4,5]imidazo[1,2-a] 
pyrimidin-2-one by the reaction of 2-aminobenzimidazole with ethylcyanoacetate. 
 
There are many other methods of pyrimidine ring synthesis which are of more 
limited scope. The reaction of 1,3-dicarbonyl compound or an equivalent reagent with 
formamide provides a route of several pyrimidine which are unsubstituted at the 2-
position. 
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PhNMeCH=CH-CHO
HCONH2
2000C
HCONHCH=CH-CHO
HCONH2
N
N
 
 
Biginelli[6] investigated that condensation of aromatic aldehyde with β-ketoester 
and urea yield the pyrimidine derivatives (VI). 
 
EtOOOC
O
H3C
Ph-CHO
H2N
O
NH2
NH
NH
EtOOC
Ph
O
H3C (VI)
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REACTION MECHANISM 
 
The reaction mechanism for the formation of pyrimidine derivatives described as 
under. 
 
R
O
H
C
C
H
R1 H2N
O
NH2 Alkali
R
O
R1
NH
O
H2N:
C
HN NH
O
R
HO
R1
C
N N
OH
R
R1
C
N N
OH
R
R1
OH-
-H+
 
 
THERAPEUTIC IMPORTANCE 
 
It is revealed from the literature survey that pyrimidine derivatives have been 
found to possessing biological activities mentioned as under. 
1. Anti HIV[7,8]
2. Antiviral[9]
3. Antimicrobial[10]
4. Herbicidal[11-17]
5. Antagonists[18-22] 
6. Antitumor[23]
7. Antiinflammatory and anticonvulsant[24,25]
8. Carcinostatic[26]
9. Antimalarial[27]
10. Antithyroid[28]
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Sanjay Batra et al.[29] have synthesized several 1-(2-cyano-3-aryl-allyl)-3-urea by 
the reaction between allylamines generated from Baylis-Hilman acetates and substituted 
isocyanates and isothiocyanate. Further, their cyclization in the presence of a base led to 
the formation of 5-arylmethyl-4-imino-3-aryl-3,4-dihydro-1H-pyrimidin-2-ones (VII) 
and were tested for their antibacterial activity. 
 
N
H
NR
NH
R1
O
(VII)
 
 
2-(Arylcarbonylmethyl)thio-6-alpha-naphthylmethyld derivatives of  dihydro 
alkoxybenzyloxopyrimidines[30] (DABO) were newly found to exhibit activity against 
both HIV-1 and HIV-2. These compounds were evaluated for their in vitro anti-HIV 
activity in MT-4 cells. The IC(50) values for anti-HIV-1 and HIV-2 were found 
moderately active. 
 
(±)-1-(anti-3-Hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-
dihydro-1H-pyrimido[4,5-d]pyrimidin-2-one (RO4383596) is a potent and selective 
inhibitor of the pro-angiogenic receptor tyrosine kinases KDR, FGFR, and PDGFR[31]. 
This agent has an excellent pharmacokinetic profile and is highly efficacious in rodent 
models of angiogenesis upon oral administration. 
 
Relationship between the topological indices and anti-HIV activity of 
dihydro(alkylthio)(napthylmethyl) oxopyrimidines (5-DABO) has been investigated by 
Lather V. and Madau A. K.[32] The use of models based upon these topological indices 
resulted in prediction of anti-HIV activity with an accuracy ranging from 86% to 89%. 
Herve Ganeste and co-workers[33] synthesized substituted 1H-pyrimidin-2-one (VIII) 
with selective dopamine D3-receptor antagonists activity. 
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HN N
N
N
NN
CF3O
HO
CH3
C
CH3H3C
CH3
(VIII)
 
 
2-Alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-
(3H) 
-ones (F (2)-NH-DABOs) 4,5 belonging to dihydro-alkoxy-benzyl-oxopyrimidine 
(DABO)[34] and bearing different alkyl and arylamino side chains at the C (2)-position of 
the pyrimidine ring were designed as active against wild type (wt) Human 
Immunodeficiency virus type 1 (HIV-1) and some relevant HIV-1 mutants.  
 
N
H
N
R1OOC
H3C O
R
H
N
H
N
O
N
R2
HN
N
H
O
COOMe
CH3
NH2
(IX) (X)
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Thirty six allyl substituted oxopyrimidine analogues[35] such as barbituric acid 
(BA), barbiturates, uracil, thymine, and related derivatives including 13 new compounds 
were synthesized and their pharmacologic effects ([hypnotic activity, anticonvulsant 
activity against pentylentetrazol (PTZ)-induced seizures, and LD(50)]) and interactions 
with the barbiturates were evaluated in mice and rats. 
Bruce M. A. and co-workers[36] have prepared the dihydropyrimidinones (IX) as 
NPY antagonists. Sidler and Larsen[37] have reported pyrimidinone derivatives (X), 
useful as an α-adrenergic receptor antagonists. 
 
Pyrimidinone derivatives[38](XI) have been found to be calcium channel blocker. 
Barbuliene M. M. et al.[4O] have synthesized pyrimidinones as antiinflammatory agent. 
 
HN
N
H
O
Ar
CH3
COOEt
HN
N
H
O
COOR
CH3
O
(XI)
 
Amuti Kofies et al.[41] have suggested pyrimidinones (XII) and (XIII) as 
herbicidal and plant growth regulators. 
N
H
NR3
R4
O
O
CH3
R3 = Alkyl, R4 = H, Halogen F Cl
O
CH
N O
CH3
F3C
(XII) (XIII)
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Swaminathan R. et al.[42] have synthesized P38 MAP Kinase inhibitors based on 
3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones (XIV) . 
N
NN
HN
O R
ClCl
X
(XIV)
 
Cano Soldado P. et al.[43] have described pyrimidine derivatives as nucleoside 
inhibitors of HIV-1. Gompel M. et al.[44] have reported new family of protein kinase 
inhibitors isolated from the ascidian aplidium meridianum. Junmei Wang et al.[45] have 
prepared hierarchical database screenings for HIV-1 Reverse Transcriptase (XV). 
HN NH
O
F
F
F
Cl
(XV)
 
 
Thus, diverse biological activities have been encountered in compounds 
containing oxopyrimidine ring system. To further assess the potential of such type of 
compounds, study of oxopyrimidines has been carried out as under. 
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SECTION-I 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(6-((Z)PHENYL)-1,2-
DIHYDRO-2-OXOPYRIMIDIN-4-YL)-2-METHYLBENZOIC ACID 
 In the past years considerable evidence has been accumulated to demonstrate the 
efficiency of pyrimidinones. 4-(6-((z)phenyl)-1,2-dihydro-2-oxopyrimidin-4-yl)-2-
methylbenzoic acid of Type (VIII) have been prepared by the condensation of methyl-4-
(3-((Z)phenyl)acryloyl)-3-methylbenzoate of Type (V) with urea in presence of basic 
catalyst as shown under. 
 
REACTION SCHEME 
 
N
O
H
N
COOH
O
OO
CH3
KOH
R
H3C H2N
O
NH2
Ethanol
R
H3C
(Type V) (Type VIII)R = H, OH, Cl, OCH3, NO2 etc.
 
 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and further 
supported by mass spectroscopy.  
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
 
  Oxopyrimidines… 
Studies on Some Heterocyclic Entities...... 
 
159
 
IR SPECTRAL STUDIES OF 4-(6-(4-FLUOROPHENYL)-1,2-DIHYDRO-2-
OXOPYRIMIDIN-4-YL)-2-METHYLBENZOIC ACID 
 
N
O
HN
COOH
CH3
F
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-
400 cm-1 (KBr disc.) 
 
Frequency cm-1
Type 
Vibration 
Mode Observed Reported 
Ref. 
Alkane 
(Methane) 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
2941 
2859 
1440 
1385 
2975-2920 
2880-2860 
1470-1435 
1395-1370 
46 
” 
” 
” 
 
Aromatic 
 
C-H str. 
C=C 
C-H i.p. def. 
C-H o.o.p. def. 
3082 
1527 
1098 
852 
3100-3000 
1585-1480 
1125-1090 
860-810 
” 
” 
” 
” 
Oxopyrimidine 
C=O str. 
C=N str. 
C–N str. 
N-H str. 
1625 
1527 
1152 
3321 
1672-1652 
1612-1593 
1220-1020 
3410-3380 
” 
” 
” 
” 
Acid 
Halide 
C=O str. 
C-F str. 
1707 
1246 
1710-1650 
1400-1100 
47 
” 
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1HNMR SPECTRAL STUDIES OF 4-(6-(4-FLUOROPHENYL)-1,2-DIHYDRO-2-
OXOPYRIMIDIN-4-YL)-2-METHYLBENZOIC ACID 
 
 
Internal Standard: TMS; Solvent: DMSO Instrument: BRUKER Spectrometer 
(400 MHz) 
 
Signal 
No. 
Signal Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
7 
 
8 
2.52 
5.50-5.52 
7.22-7.24 
7.34-7.38 
7.40-7.43 
7.47 
7.78-7.88 
 
12.91 
3H 
1H 
2H 
2H 
1H 
1H 
2H 
 
1H 
singlet 
doublet 
triplet 
multiplet 
doublet 
Singlet 
multiplet 
 
singlet 
-CH3
-CH (d)(J= 4.8 Hz) 
Ar-CH (f,f’) 
Ar-CH (e,e’) 
Ar-CH (c) (J= 9.2 Hz) 
Ar-CH (a) 
Ar-CH(b)  
and –NH 
-COOH 
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EXPANDED REGION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(6-((Z)PHENYL)-1,2-
DIHYDRO-2-OXOPYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
 
[A] SYNTHESIS OF METHYL 4-((E)-3-(4-FLOUROPHENYL)ACRYLOYL)-
2-METHYLBENZOATE 
 
 See Part-IV, Experimental Section-[B]. 
 
[B] SYNTHESIS OF 4-(6-(4-FLUOROPHENYL)-1,2-DIHYDRO-2-
OXOPYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
 
A mixture of methyl 4-((E)-3-(4-flourophenyl)acryloyl)-2-methylbenzoate (0.01 
mol, 2.98 gm) and urea (0.01 mol, 0.6 gm) in ethanol (20 ml) was refluxed on waterbath 
in presence of alcoholic KOH for 12 hrs. The excess solvent was distilled off and the 
residue was neutralized with 20% HCl, the separated solid was filtered out and 
crystallized from methanol. Yield 71 %, m.p. 1100C.  
 
Similarly, other 4-(6-((Z)phenyl)-1,2-dihydro-2-oxopyrimidin-4-yl)-2-methyl 
benzoic acid were prepared. The physical data are recorded in Table 13. 
 
[C] BIOLOGICAL EVALUATION OF 4-(6-((Z)PHENYL)-1,2-DIHYDRO-2-
OXOPYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
 
 Antimicrobial testing were carried out as described in Part-II, Experimental 
Section-I [C]. The results of test solutions are recorded in Table 14. 
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TABLE 14:  BIOLOGICAL EVALUATION OF 4-(6-((Z)PHENYL)-1,2-
DIHYDRO-2-OXOPYRIMIDIN-4-YL)-2-METHYL BENZOIC 
ACID  
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml 
Gram +ve Bacteria Gram –ve Bacteria 
Minimal fungicidal concentration 
μg/ml Sr. 
No. Code  
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1 7a   100 250 500 100 250 500 1000 
2 7b 500 500 1000 1000 500 500 200 
3 7c 500 500 200 50 250 250 500 
4 7d 250 1000 500 1000 500 500 500 
5 7e 200 100 1000 500 >1000 1000 500 
6 7f 50 1000 50 250 1000 200 250 
7 7g 1000 250 500 200 500 500 1000 
8 7h 250 200 200 1000 1000 1000 >1000 
9 7i 250 250 100 1000 1000 >1000 250 
10 7j 200 100 1000 250 500 500 500 
11 7k 500 1000 250 250 500 1000 1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
E.coli P.aeruginosa S.aureus S.pyogenus 
Standard Drugs 
(microgramme/ml) 
Gentamycin 0.05 1 0.25 0.5 
Ampicillin 100 100 250 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 25 25 50 50 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
C.Albicans A.Niger A.Clavatus 
Standard Drugs 
(microgramme/ml) 
 Nystatin 100 100 100 
Greseofulvin 500 100 100 
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ANTIBACTERIAL ACTIVITY:  
From screening results, substituted Oxopyrimidines 7f (R = -4-Cl) against 
S.aureus and E.coli while 7c (R = -4-OH) possesses very good activity against 
P.aeruginosa as compared with ampicillin. 7a (R = -2-OH) against S.aureus, 7e (R = -4-
OH-3-OCH3) and 7j (R = -2-Cl) against S.pyogenus, 7i (R = -4-OCH3) against E.coli 
and 7a (R = -2-OH) against P.aeruginosa possesses moderate activity as compared with 
ampicillin. The remaining oxopyrimidine derivatives possess poor to very poor activity 
against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY: 
 
Antifungal screening data showed that substituted Oxopyrimidines 7f (R = -4-Cl) 
against A.niger and 7b (R = -3-NO2) against A.clavatus show highly promising activity 
compare with standard drug. While 7a (R = -2-OH) and 7c (R = -4-OH) against 
C.albicans, 7c (R = -H) against A.niger, 7f (R = -4-Cl) and 7i (R = -4-OCH3) against 
A.clavatus exhibited moderate activity. The remaining compounds exhibited poor 
activity against all three bacterial species.  
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INTRODUCTION 
 
Pyrimidine is the most important member of all the diazines as this ring system 
occurs widely in living organisms. Pyrimidine and its derivatives have gained 
prominence because of their potential pharmaceutical values. Many pyrimidine 
derivatives play vital role in many physiological actions. They are among those 
molecules that make life possible as being some of the building blocks of DNA and 
RNA. 
 
N NH
S
N N
NH2
 
 
Pyrimidine is considered to be a resonance hybrid of the charged and uncharged 
cannonical structures, its resonance energy has been found to be less than benzene or 
pyridine. The naturally occurring pyrimidine derivative was first isolated by Gabrial and 
Colman in 1870, and its structure was confirmed in 1953 as 5-β-D-gluco-pyranoside of 
divicine. 
Some pyrimidines of physiologically as well as pharmacologically importance 
are as under: e.g., cytosine, bedmethrin (I) and trimethoprim (II). 
N
N
NH2
HOH2C
O
CH3
N
N
NH2
NH2C2H5
Cl
(I) (II)
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Pyrimidine is considered to be a resonance hybrid of the charged and uncharged 
cannonical structures; its resonance energy has been found to be less than benzene or 
pyridine. 
SYNTHETIC ASPECT 
A very important general method for preparing pyrimidines is the condensation 
between a three carbon compounds of the type YCH2Z, where Y and Z = COR, CO2R, 
CN, and compounds having the amidine structure R(C=NH)NH2, where R = R (an 
amidine), SH or SR (thiourea or its s-derivative), NH2 (guanidine); the condensation is 
carried out in the presence of sodium hydroxide or sodium ethoxide. This general 
reaction may be illustrate by the condensation of acetamidine with ethylacetoacetate to 
form 4-hydroxy-2,6-dimethylpyrimidine. 
Pyrimidines has been synthesised by different methods, which has been 
described in literature[1-4]. 
 
1. Rasaki[5] synthesised 2-aminopyrimidines by the reaction of chalcone epoxides 
with guanidine carbonate in xylene. 
 
HN
N S
O
O
N
NH
SS
H3C
H3C
CH3 H3C
CH3
CH3
 
 
2.  The reaction of chalcone with guanidine hydrochloride in presence of potassium-
t-butoxide in t-butanol yielded corresponding 2-aminopyrimidine derivatives[6]. 
3.  Abd-El-gali E. Amr[7] synthesised 2-aminopyrimidines by the reaction of 
chalcones with guanidine hydrochloride in the presence of NaOH. 
4. The reaction of chalcone with guanidine hydrochloride in presence of potassium 
butoxide in t-butanol yielded corresponding 2-amino pyrimidine derivatives[8]. 
Pratibha Sharma and co-workers[9] have investigated the insertion of 
dimethylvinylidene carbine into azo moiety was investigated in order to 
synthesize 4,6-dimethyl-5-[2-(2-methylprop-1-enyl)-1H-benzimidazol-1-yl] 
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Pyrimidine-2(5H)-thiones under kinetically controlled phase transfer catalysis 
conditions. 
 
N
N
H3C
CH3
N
N
S
CH3
H3C
R
 
 
 
There are many other methods of pyrimidine ring synthesis which are of more 
limited scope. The reaction of 1,3-dicarbonyl compound or an equivalent reagent with 
formamide provides a route of several pyrimidine which are unsubstituted at the 2-
position. 
 
 
PhNMeCH=CH-CHO
HCONH2
2000C
HCONHCH=CH-CHO
HCONH2 N
N
 
 
 
REACTION MECHANISM 
The reaction mechanism for the formation of pyrimidine derivatives described as 
under. 
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R
O
H
C
C
H
R1 H2N
R2
NH2 Alkali
R
O
R1
NH
R2
H2N:
C
HN NH
R2
R
HO
R1
C
N N
R2
R
R1
C
N N
R2
R
R1
OH-
-H+
R2 = NH2, SH
 
 
THERAPEUTIC EVALUATION 
Pyrimidine derivatives exhibit a wide spectrum of pharmacological activities few 
of them are as under. 
1.  Antitubercular[10]
2.  Antidiabetic[11]
3.  Anticonvulsant[12]
4.  Fungicidal[13]
5.  Insecticidal[14]
6.  Analgesic[15]
7.  Tranquilizing[16]
8.  Antibacterial[17]
9.  Diuretic[18]
10.  Antihypertensive[19]
 
Large number of drugs possesses pyrimidine ring system. Well-known 
antimalarial agents like trimethoprim (III) and pyrimethamine (IV), hypotensive agent 
like minoxidil (V), antibacterial agent like ormetraprim (VI) possess aminopyrimidine 
ring system. 
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N N
H3CO
OCH3
OCH3
NH2
NH2
N N
H3CO CH3
NH2
NH2H3C
N N
NH2
NH2H2N
N N
NH2
NH2
H
N
(III) (IV)
(V) (VI)
 
 
Gangjee A. et al.[20] Synthesised aminopyrimidines which possess antitumor 
activity. Pan S.[21] prepared 2-methylthio-4-amino-6-(3,5-diacetylphenylamino) 
pyrimidines which show anti HIV activity in Hq cell cultures. Ugarkar B. et al.[22] found 
aminopyrimidines in the inhibition of cardiovascular and ceribrovascular disorders. 
Some aminopyrimidines have been studied for their antimicrobial activity[23]. 
Bargiotti A. et al.[24] prepared aminopyrimidine derivatives for their therapeutic 
use as telomerase inhibitors and anticancer agent. Jden and Juan[25] synthesised some 
new aminopyrimidines for the treatment of cytomegalovirus infections. Tsutsumi H. et 
al.[26] prepared aminopyrimidine (VII) as adenosine receptor antagonists. Some novel 
aminopyrimidine derivatives (VIII) have been evaluated as dihydrofolate reductase 
inhibitors[27]. 
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N
NH2N
N
NH
O
N
N
NH2
H2N
N
CH3
O
O
OCH3
(VII) (VIII)
 
S. S. Sangapure[28] have tested the antimicrobial activity of benzofuro[3,2-
d]pyrimidine derivatives (IX). El Sayed[29] have synthesized alkylated substituted 
mercapto pyrimidine derivatives (X) and studied their anticancer and antineoplastic 
activity. H. Y. Moustafa[30] have reported some pyrimidine derivatives and studied their 
biological activities. 
 
 
O
N
HN
S
NH2
N
NH3CS
Cl
CH3
(IX) (X)
 
 
Patil L. R. et al.[31] have synthesized some new pyrimidines bearing paracetamol 
and imidazolyl moieties. B. J. Ghiya et al.[32] synthesized some mercapto Pyrimidine 
derivatives (X) and screened for their anticancer, antitubercular and anti HIV activities. 
Kaplina N. V. and co-workers[33] shows herpes inhibiting activity of some mercapto 
pyrimidine derivatives (XI). 
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CH3
R2
R1
H
N
N N
NH2
R3
(XI)
 
 
 
N N
SH
R4
R3
R2
R1
(XII)
R5
 
 
Patricia F. et al.[34] have prepared 2-tosyliminopyrimidine derivatives as 
inhibitors of some leukocyte functions. Some pyrimidine derivatives showing 
significant biological activity have been reported[35] Aleem G. et al.[36] have prepared 
aminopyrimidine derivatives of glutamic acid as potential dual inhibitors of 
dihydrofolate reductase and as potential antitumor agents. 
 
Viney Lather and co-workers[37] have been proposed to predict the anti-HIV 
activity of dihydro(alkylthio)(naphthylmethyl)oxopyrimidines. These models are 
capable of providing lead structures for development of potent but safe anti-HIV agents 
(XIII). 
 
 
 
  Pyrimidines… 
Studies on Some Heterocyclic Entities...... 
 
177
HN
NHS
O
R1
R
(XIII)
 
 
Mai A. et al.[38] have synthesized 5-alkyl-2-alkylamino-6-(2,6-
difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-
spectrum nonnucleoside reverse transcriptase inhibitors belonging to the DABO family. 
Yamamoto I. et al.[39] have reported some oxopyrimidines searching for the novel 
antagonist or agonist of barbiturates to the sleep mechanism based on the uridine 
receptor. Huang Y. L. et al.[40] have synthesized non-classical antifolates, 5-(N-
phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines and 2,4-diamino-6(5H)-
oxopyrimidines as antitumor activity. 
 
Shimizu T. et al.[41] have described N3-substituted uridine and related 
Pyrimidine nucleosides as antinociceptive effects in mice. Sanmartin C. et al.[42] have 
prepared new symmetrical derivatives as cytotoxic agents and apoptosis inducers. 
Agarwal A. et al.[43] have synthesized 2,4,6-trisubstituted pyrimidine derivatives as 
pregnancy interceptiveagents. Shigeta S. et al.[44] have been synthesized 5-alkyl-2-
thiopyrimidine nucleoside analogues and examined for antiviral activities against Herps 
Simplex virus (HSV), Varicella-Zoster virus (SZV) and Human Cytomegalo virus 
(HCMV). 
 
A. Nagaraj and C. Sanjeeva Reddy[45]have prepared a series of novel bis-
chalcones and corresponding bispyrimidines (XIV, XV) and reported antibacterial, 
antifungal and anti-inflammatory activities. 
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N S S N
R R
NH2 NH2
OHHO
(XIV)
 
 
N N N N
R R
NH2 NH2
OHHO
(XV)
 
Looking to the diversified activities exhibited and in continuation of our work on 
the synthesis of biologically active heterocycles, the synthesis and biological screening 
of pyrimidine derivatives have been described as under. 
 
 
 
 
 
SECTION I: SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2-    
AMINO-6-((Z)PHENYL)PYRIMIDIN-4-YL)-2-METHYL 
BENZOIC ACID 
 
 
SECTION II: SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(6-((Z) 
PHENYL)-1,2-DIHYDRO-2-THIOXOPYRIMIDIN-4-YL)-2-
METHYLBENZOIC ACID 
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SECTION I 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2-AMINO-6-((Z) 
PHENYL)PYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
 
 Aminopyrimidines represent one of the most active classes of compounds 
possessing a wide spectrum of biological activities, such as significant in vitro activity 
against DNA and RNA viruses including polio viruses, diuretic, antitubercular 
spermicidal etc. These valid observation let us to synthesize 4-(2-amino-6-
((Z)phenyl)pyrimidin-4-yl)-2-methyl benzoic acid of Type (IX) by cyclocondensation of 
4-((E)-3-(4-flourophenyl)acryloyl)-2-methylbenzoate of Type (V) and guanidine 
hydrochloride in presence of KOH as catalyst.  
 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and 
further supported by mass spectroscopy.  
 
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
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REACTION SCHEME 
 
CH3
H3COOC
O
R
Type (V)
H2N
C
NH2
NH
.HClKOH
HOOC
CH3
NN
NH2
R
Type (IX)
R= H, OH, Cl, NO2, OCH3 etc.
Ethanol
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IR SPECTRAL STUDIES OF 4-(2-AMINO-6-(4-
FLUOROPHENYL)PYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
 
N
NH2
N
COOH
CH3
F
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc.) 
 
 
Frequency cm-1Type Vibration Mode Observed Reported Ref. 
Alkane 
(Methane) 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
2963 
2820 
1511 
1380 
2975-2920 
2880-2860 
1470-1435 
1395-1370 
46 
” 
” 
” 
 
Aromatic 
 
C-H str. 
C=C 
C-H i.p. def. 
C-H o.o.p. def. 
2998 
1549 
1159 
840 
3100-3000 
1585-1480 
1125-1090 
860-810 
” 
” 
” 
” 
Pyrimidine 
 
Amine 
Halide 
C=N str. 
C–N str. 
N-H str. 
C-F str. 
1511 
1228 
3397 
1258 
1580-1520 
1220-1020 
3410-3380 
1400-1100 
” 
” 
” 
47 
Acid C=O str. 1704 1710-1650 ” 
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1H NMR SPECTRAL STUDIES OF 4-(2-AMINO-6-(4-FLUOROPHENYL) 
PYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
 
Internal Standard: TMS; Solvent: DMSO Instrument: BRUKER Spectrometer 
(400 MHz) 
 
Signal 
No. 
Signal Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
7 
8 
2.61 
6.85 
7.25-7.30 
7.56 
7.78-7.85 
7.91-7.93 
8.09-8.15 
8.29-8.33 
3H 
1H 
2H 
2H 
2H 
1H 
1H 
1H 
singlet 
singlet 
triplet 
singlet 
multiplet 
doublet 
multiplet 
multiplet 
-CH3  
Ar-CH (d) 
Ar-CH (f,f’) 
-NH2
Ar-CH (e,e’) 
Ar-CH (a)(J=8.0 Hz) 
Ar-CH (c) 
Ar-CH (b) 
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EXPANDED AROMATIC REGION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(2-AMINO-6-
((Z)PHENYL)PYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
 
 
[A] SYNTHESIS OF METHYL 4-((E)-3-(4-FLOUROPHENYL)ACRYLOYL)-
2-METHYLBENZOATE 
 
 See Part-IV, Experimental Section-[B]. 
 
[B] SYNTHESIS OF 4-(2-AMINO-6-(4-FLUOROPHENYL)PYRIMIDIN-4-
YL)-2-METHYL BENZOIC ACID 
 
A mixture of methyl 4-((E)-3-(4-flourophenyl)acryloyl)-2-methylbenzoate (0.01 
mol, 2.98 gm) and guanidine hydrochloride (0.01 mol, 0.95 gm) in ethanol (20 ml) was 
refluxed on waterbath in presence of alcoholic KOH for 10 hrs. The excess solvent was 
distilled off and the residue was neutralized with 10% HCl, the separated solid was 
filtered out and crystallized from ethanol. Yield 70 %, m.p. 2400C.  
 
 Similarly, other 4-(2-Amino-6-((Z)phenyl)Pyrimidin-4-Yl)-2-Methyl benzoic 
acid  were prepared. The physical data are recorded in Table 15. 
 
[C] BIOLOGICAL EVALUATION OF 4-(2-AMINO-6-((Z)PHENYL)PYRIMI -
DIN-4-YL)-2-METHYL BENZOIC ACID 
 
 Antimicrobial testing were carried out as described in Part-II, Experimental 
Section-I [C]. The results of test solutions are recorded in Table 16. 
 
 
 
 
  Pyrimidines… 
Studies on Some Heterocyclic Entities...... 
 
186
 
   
Sr
.  
   
   
   
   
   
R
   
   
   
   
   
   
   
   
   
   
  M
ol
ec
ul
ar
   
  M
ol
ec
ul
ar
   
   
  M
.P
.  
   
  Y
ie
ld
   
   
   
  %
 o
f N
itr
og
en
   
   
   
  R
f  
   
   
   
   
So
lv
en
t  
   
   
   
N
o.
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Fo
rm
ul
a 
   
   
  W
ei
gh
t  
   
   
   
  0
C
   
   
   
   
 %
   
   
   
C
al
cd
.  
   
   
 F
ou
nd
   
   
 V
al
ue
   
   
   
Sy
st
em
 
   
 1
   
   
   
   
   
   
  2
   
   
   
   
   
   
   
   
   
   
   
   
  3
   
   
   
   
   
   
  4
   
   
   
   
   
   
  5
   
   
   
   
  6
   
   
   
   
   
 7
   
   
   
   
   
   
8 
   
   
   
   
   
 9
   
   
   
   
   
  1
0 
   
  8
a 
   
   
   
2-
hy
dr
ox
y 
   
   
   
   
   
   
   
 C
18
H
15
N
3O
3  
   
   
 3
21
.3
3 
   
   
   
 1
39
   
   
   
   
  5
4 
   
   
   
  1
3.
08
   
   
   
 1
3.
10
   
   
   
  0
.4
2 
   
   
   
   
S 1
   
  8
b 
   
   
   
3-
N
itr
o 
   
   
   
   
   
   
   
   
  C
18
H
14
N
4O
4  
   
   
 3
50
.3
3 
   
   
   
 1
99
   
   
   
   
   
45
   
   
   
  1
5.
99
   
   
   
  1
5.
97
   
   
   
  0
.4
4 
   
   
   
   
S 1
   
  8
c 
   
   
   
4-
H
yd
ro
xy
   
   
   
   
   
   
   
C
18
H
15
N
3O
3  
   
   
 3
21
.3
3 
   
   
   
  1
42
   
   
   
   
  5
0 
   
   
   
  1
3.
08
   
   
   
 1
3.
07
   
   
   
  0
.4
3 
   
   
   
   
S 1
   
  8
d 
   
   
   
4-
N
,N
-D
im
et
hy
l  
   
   
   
 C
20
H
20
N
4O
2  
   
   
34
8.
40
   
   
   
   
17
5 
   
   
   
   
 5
7 
   
   
   
  1
6.
08
   
   
   
 1
6.
11
   
   
   
  0
.4
9 
   
   
   
   
 S
1
   
  8
e 
   
   
   
4-
H
yd
ro
xy
-3
-M
et
ho
xy
  C
19
H
17
N
3O
4  
   
   
35
1.
36
   
   
   
   
15
1 
   
   
   
   
 4
3 
   
   
   
  1
1.
96
   
   
   
 1
1.
94
   
   
   
  0
.4
0 
   
   
   
   
 S
1
   
  8
f  
   
   
  4
-C
hl
or
o 
   
   
   
   
   
   
   
   
C
18
H
14
C
lN
3O
2  
  3
39
.7
8 
   
   
   
  1
80
   
   
   
   
  5
9 
   
   
   
  1
2.
37
   
   
   
 1
2.
38
   
   
   
  0
.4
7 
   
   
   
   
 S
1
   
  8
g 
   
   
   
4-
N
itr
o 
   
   
   
   
   
   
   
   
  C
18
H
14
N
4O
4  
   
   
35
0.
33
   
   
   
   
 2
33
   
   
   
   
 4
7 
   
   
   
  1
5.
99
   
   
   
 1
6.
01
   
   
   
  0
.5
0 
   
   
   
   
 S
1
   
  8
h 
   
   
   
H
   
   
   
   
   
   
   
   
   
   
   
  C
18
H
15
N
3O
2  
   
   
 3
05
.3
3 
   
   
   
   
21
0 
   
   
   
   
53
   
   
   
   
13
.7
6 
   
   
   
13
.7
5 
   
   
   
 0
.5
1 
   
   
   
   
 S
1 
   
  8
i  
   
   
  4
-M
et
ho
xy
   
   
   
   
   
   
   
C
19
H
17
N
3O
3  
   
   
 3
35
.3
6 
   
   
   
  1
66
   
   
   
   
  6
2 
   
   
   
  1
2.
53
   
   
   
 1
2.
56
   
   
   
  0
.4
6 
   
   
   
   
 S
1
   
  8
j  
   
   
  2
-C
hl
or
o 
   
   
   
   
   
   
   
  C
18
H
14
C
lN
3O
2  
   
 3
39
.7
8 
   
   
   
 1
93
   
   
   
   
  6
8 
   
   
   
   
12
.3
7 
   
   
   
12
.3
8 
   
   
   
 0
.4
5 
   
   
   
   
S 1
   
  8
k 
   
   
  4
-F
lu
or
o 
   
   
   
   
   
   
   
  C
18
H
14
FN
3O
2  
   
   
32
3.
32
   
   
   
   
24
0 
   
   
   
   
 7
0 
   
   
   
  1
3.
00
   
   
   
 1
2.
98
   
   
   
  0
.4
2 
   
   
   
   
S 1
TA
BL
E 
15
 : 
PH
Y
SI
C
A
L
 C
O
N
ST
A
N
T
S 
O
F 
4-
(2
-A
M
IN
O
-6
-(
(Z
)P
H
EN
Y
L)
PY
R
IM
I D
IN
-4
-Y
L
)-
2-
M
ET
H
Y
LB
EN
ZO
IC
 A
C
ID
  
S 1
-T
ol
ue
ne
 : 
M
et
ha
no
l- 
 7
 : 
3 
 
  Pyrimidines… 
Studies on Some Heterocyclic Entities...... 
 
187
TABLE 16:  BIOLOGICAL EVALUATION OF 4-(2-AMINO-6-((Z)PHENYL) 
 PYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml 
Gram +ve Bacteria Gram –ve Bacteria 
Minimal fungicidal concentration 
μg/ml Sr. 
No. Code  
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1 8a   50 250 250 500 200 250 >1000 
2 8b 500 1000 100 62.5 500 >1000 250 
3 8c 1000 100 200 200 500 250 500 
4 8d 200 200 1000 250 250 200 1000 
5 8e 1000 100 500 500 1000 500 500 
6 8f 100 500 100 100 500 >1000 200 
7 8g 250 500 250 500 500 500 250 
8 8h 200 50 250 250 1000 1000 >1000 
9 8i 200 200 1000 100 >1000 500 500 
10 8j 1000 250 500 1000 500 500 1000 
11 8k 200 100 200 200 250 1000 500 
 
MINIMAL INHIBITION CONCENTRATION 
 
E.coli P.aeruginosa S.aureus S.pyogenus 
Standard Drugs 
(microgramme/ml) 
Gentamycin 0.05 1 0.25 0.5 
Ampicillin 100 100 250 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 25 25 50 50 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
C.Albicans A.Niger A.Clavatus 
Standard Drugs 
(microgramme/ml) 
 Nystatin 100 100 100 
Greseofulvin 500 100 100 
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ANTIBACTERIAL ACTIVITY:  
From screening results, substituted 2-amino Pyrimidine derivatives 8a (R = -2-
OH) against S.aureus, 8h (R = -H) against S.pyogenus and 8b (R = -3-NO2) against 
P.aeruginosa possesses very good activity as compared with  standard drug ampicillin 
while 8f (R = -4-Cl) against S.aureus,  8c (R = -4-OH), 8e (R = -4-OH-3-OCH3) and 8k 
(R = -4-F) against S.pyogenus, 8b (R = -3-NO2) and 8f (R = -4-Cl)  against E.coli, 8f (R 
= -4-Cl) and 8i (R = -4-OCH3) against P.aeruginosa possesses moderate activity as 
compared with ampicillin. The remaining 2-amino pyrimidine derivatives possess poor 
to very poor activity against all four bacterial species.  
 
ANTIFUNGAL ACTIVITY: 
 
Antifungal screening data showed that substituted 2-amino pyrimidine 
derivatives 8a (R = -2-OH) against A.clavatus, 8d (R = -4-N,N(CH3)2) against A.niger 
and 8f (R = -4-Cl) A.clavatus show highly promising activity compare with standard 
drug. While 8d (R = -4-N,N(CH3)2) and 8k (R = -4-F) against A.clavatus, 8a (R = -2-
OH) and 8c (R = -4-OH) against A.niger, 8b (R = -3-NO2) and 8f (R = -4-Cl) against 
A.clavatus, exhibited moderate activity. The remaining compounds exhibited poor 
activity against all three bacterial species. 
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SECTION-II 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(6-((Z)PHENYL)-1,2-
DIHYDRO-2-THIOXOPYRIMIDIN-4-YL)-2-METHYLBENZOIC ACID 
 
 Compounds containing pyrimidine ring are widely available in nature. Many thio 
pyrimidine derivatives are reported to possess different therapeutic activities. In view of 
these findings, it was considered worthwhile to synthesize some new 4-(6-((Z)phenyl)-
1,2-dihydro-2-thioxopyrimidin-4-yl)-2-methylbenzoic acid  of Type (X) to study their 
therapeutic activities. Thio pyrimidine derivatives of Type (X) have been prepared by 
the reaction of the chalcones of Type (V) with thiourea in presence of basic catalyst in 
ethanol shown as under. 
The constitution of the synthesized products have been characterized by using 
elemental analysis, infrared and 1H-nuclear magnetic resonance spectroscopy and 
further supported by mass spectroscopy.  
All the compounds have been evaluated for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different 
concentration. The biological activities of synthesized compounds were compared with 
standard drugs. 
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REACTION SCHEME 
 
CH3
H3COOC
O
R
Type (V)
H2N
C
NH2
S
KOH
HOOC
CH3
NHN
S
R
Type (X)
R= H, OH, Cl, NO2, OCH3 etc.
Ethanol
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IR SPECTRAL STUDIES OF 4-(6-(4-FLUOROPHENYL)-1,2-DIHYDRO-2-
THIOXOPYRIMIDIN-4-YL)-2-METHYLBENZOICACID 
 
N
S
HN
COOH
CH3
F
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc.) 
 
 
Frequency cm-1Type Vibration Mode Observed Reported Ref. 
Alkane 
(Methane) 
C-H str. (asym.) 
C-H str. (sym.) 
C-H def. (asym.) 
C-H def. (sym.) 
2929 
2880 
1444 
1287 
2975-2920 
2880-2860 
1470-1435 
1395-1370 
46 
” 
” 
” 
 
Aromatic 
 
C-H str. 
C=C 
C-H i.p. def. 
C-H o.o.p. def. 
3109 
1571 
1166 
836 
3100-3000 
1585-1480 
1125-1090 
860-810 
” 
” 
” 
” 
Thio Pyrimidine 
Amine 
Vinyl 
Halide 
C=S str. 
N-H str. 
CH=CH str. 
C-F str. 
1571 
3343 
3109 
1236 
1590-1550 
3554-3350 
3050-3000 
1400-1100 
” 
” 
” 
47 
Acid C=O str. 1697 1710-1650 ” 
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1H NMR SPECTRAL STUDIES OF 4-(6-(4-FLUOROPHENYL)-1,2-DIHYDRO-
2-THIOXO PYRIMIDIN-4-YL)-2-METHYLBENZOICACID 
 
Internal Standard: TMS; Solvent: DMSO Instrument: BRUKER Spectrometer 
(400 MHz) 
 
Signal 
No. 
Signal Position 
δppm 
Relative No. 
of Protons 
Multiplicity Inference 
1 
2 
3 
4 
5 
6 
7 
8 
2.50 
5.51-5.52 
7.22-7.27 
7.35-7.38 
7.41-7.43 
7.48 
7.79-7.81 
13.0 
3H 
1H 
2H 
2H 
1H 
1H 
1H 
1H 
Singlet 
triplet 
multiplet 
triplet 
doublet 
singlet 
multiplet 
singlet 
-CH3
-CH (d) 
Ar-CH (e,e’) 
Ar-CH (f,f’) 
Ar-CH (b)(J=8.0 Hz) 
Ar-CH (a) 
Ar-CH (c) 
-COOH 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-(6-((Z)PHENYL)-1,2-
DIHYDRO-2-THIOXOPYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
 
 
[A] SYNTHESIS OF METHYL 4-((E)-3-(4-FLOUROPHENYL)ACRYLOYL)-
2-METHYLBENZOATE 
 
 See Part-IV, Experimental Section-[B]. 
 
[B] SYNTHESIS OF 4-(6-(4-FLUOROPHENYL)-1,2-DIHYDRO-2-
THIOXOPYRIMIDIN-4-YL)-2-METHYL BENZOIC ACID 
 
A mixture of  methyl 4-((E)-3-(4-flourophenyl)acryloyl)-2-methylbenzoate (0.01 
mol, 2.98 gm) and thiourea (0.01 mol, 0.76 gm) in ethanol (20 ml) was refluxed on 
waterbath in presence of alcoholic KOH for 10-13 hrs. The excess solvent was distilled 
off and the residue was neutralized with 20% HCl, the separated solid was filtered out 
and crystallized from ethanol. Yield 72 %, m.p. 2150C.  
 Similarly, other 4-(6-((Z)phenyl)-1,2-dihydro-2-thioxopyrimidin-4-yl)-2-methyl 
benzoic acid  were prepared. The physical data are recorded in Table 17. 
 
[C] BIOLOGICAL EVALUATION OF 4-(6-((Z)PHENYL)-1,2-DIHYDRO-2-
THIOXOPYRIMIDIN-4-YL)-2-METHYLBENZOICACID 
 
 Antimicrobial testing was carried out as described in Part-II, Experimental 
Section-I [C]. The results of test solutions are recorded in Table 18. 
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TABLE 18:  BIOLOGICAL EVALUATION OF 4-(6-((Z)PHENYL)-1,2-DIHYDRO-
2-THIOXOPYRIMIDIN-4-YL)-2-METHYLBENZOICACID 
Antibacterial Activity Antifungal activity 
Minimal bactericidal concentration μg/ml 
Gram +ve Bacteria Gram –ve Bacteria 
Minimal fungicidal concentration 
μg/ml Sr. 
No. Code  
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus 
1 9a   100 200 50 1000 1000 500 500 
2 9b 250 1000 200 500 500 >1000 200 
3 9c 500 100 1000 500 250 500 1000 
4 9d 250 500 100 1000 200 1000 250 
5 9e 250 1000 500 100 500 1000 1000 
6 9f 62.5 250 250 500 >1000 250 500 
7 9g 100 500 250 250 >1000 200 1000 
8 9h 500 500 500 1000 500 500 250 
9 9i 1000 1000 250 62.5 200 500 >1000 
10 9j 1000 500 100 250 500 >1000 500 
11 9k 200 250 500 500 500 500 1000 
 
MINIMAL INHIBITION CONCENTRATION 
 
E.coli P.aeruginosa S.aureus S.pyogenus 
Standard Drugs 
(microgramme/ml) 
Gentamycin 0.05 1 0.25 0.5 
Ampicillin 100 100 250 100 
Chloramphenicol 50 50 50 50 
Ciprofloxacin 25 25 50 50 
Norfloxacin 10 10 10 10 
MINIMAL FUNGICIDAL CONCENTRATION 
C.Albicans A.Niger A.Clavatus 
Standard Drugs 
(microgramme/ml) 
 Nystatin 100 100 100 
Greseofulvin 500 100 100 
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ANTIBACTERIAL ACTIVITY:  
From screening results, substituted thioPyrimidine derivatives 9f (R = -4-Cl) 
against S.aureus, 9a (R = -2-OH) against E.coli and 9i (R = -4-OCH3) against 
P.aeruginosa  possesses very good activity as compared with  standard drug ampicillin 
while 9a (R = -2-OH) and 9j (R = -2-Cl) against S.aureus,  9c (R = -4-OH)against 
S.pyogenus, 9e (R = -4-OH-3-OCH3) and 9j (R = -2-Cl)  against E.coli, 9e (R = -4-OH-
3-OCH3) against P.aeruginosa possesses moderate activity as compared with ampicillin. 
The remaining 2-thiopyrimidine derivatives possess poor to very poor activity against 
all four bacterial species.  
 
ANTIFUNGAL ACTIVITY: 
 
Antifungal screening data showed that substituted thiopyrimidine derivatives 9d 
(R = -4-N,N(CH3)2) and 9i (R = -4-OCH3) against C.albicans, 9g (R = -4-NO2) against 
A.niger and 9b (R = -3-NO2) against A.clavatus show highly promising activity 
compare with standard drug. While 9c (R = -4-OH) against C.albicans, 9f (R = -4-Cl) 
against A.niger, 9d (R = -4-N,N(CH3)2) and 9h (R = H) against A.clavatus exhibited 
moderate activity as compare with standard drug. The remaining compounds exhibited 
poor activity against all three bacterial species. 
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